Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Feb. 22, 2022 | Jun. 30, 2021 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 001-36046 | ||
Entity Registrant Name | AXOGEN, INC. | ||
Entity Incorporation, State or Country Code | MN | ||
Entity Tax Identification Number | 41-1301878 | ||
Entity Address, Address Line One | 13631 Progress Blvd., Suite 400 | ||
Entity Address, City or Town | Alachua | ||
Entity Address, State or Province | FL | ||
Entity Address, Postal Zip Code | 32615 | ||
City Area Code | 386 | ||
Local Phone Number | 462-6800 | ||
Title of 12(b) Security | Common Stock, $0.01 par value | ||
Trading Symbol | AXGN | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 641,907,222 | ||
Entity Common Stock, Shares Outstanding | 41,795,240 | ||
Documents Incorporated by Reference | Portions of the Registrant’s definitive proxy statement to be filed pursuant to Regulation 14A within 120 days after the end of the Registrant’s fiscal year are incorporated by reference into Part III of this Form 10-K. | ||
Entity Central Index Key | 0000805928 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2021 | |
Audit Information [Abstract] | |
Auditor Firm ID | 34 |
Auditor Name | Deloitte & Touche LLP |
Auditor Location | Miami, Florida |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 32,756 | $ 48,767 |
Restricted cash | 6,251 | 6,842 |
Investments | 51,330 | 55,199 |
Accounts receivable, net of allowance for doubtful accounts of $276 and $416, respectively | 18,158 | 17,618 |
Inventory | 16,693 | 12,529 |
Prepaid expenses and other | 1,861 | 4,296 |
Total current assets | 127,049 | 145,251 |
Property and equipment, net | 62,881 | 38,398 |
Operating lease right-of-use assets | 15,193 | 15,614 |
Finance lease right-of-use assets | 42 | 64 |
Intangible assets, net | 2,859 | 2,054 |
Total assets | 208,024 | 201,381 |
Current liabilities: | ||
Accounts payable and accrued expenses | 22,459 | 21,968 |
Current maturities of long-term lease obligations | 1,834 | 863 |
Total current liabilities | 24,293 | 22,831 |
Long-term debt, net of financing fees | 44,821 | 32,027 |
Long-term lease obligations | 20,798 | 20,874 |
Debt derivative liabilities | 5,562 | 2,497 |
Other long-term liabilities | 0 | 3 |
Total liabilities | 95,474 | 78,232 |
Commitments and contingencies - see Note 14 | ||
Shareholders’ equity: | ||
Common stock, $0.01 par value per share; 100,000,000 shares authorized; 41,736,950 and 40,618,766 shares issued and outstanding | 417 | 406 |
Additional paid-in capital | 342,765 | 326,390 |
Accumulated deficit | (230,632) | (203,647) |
Total shareholders’ equity | 112,550 | 123,149 |
Total liabilities and shareholders’ equity | $ 208,024 | $ 201,381 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Accounts receivable, allowance for doubtful accounts | $ 276 | $ 416 |
Shareholders’ equity: | ||
Common stock, par value (in USD per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 41,736,950 | 40,618,766 |
Common stock, shares outstanding (in shares) | 41,736,950 | 40,618,766 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Statement [Abstract] | |||
Revenues | $ 127,358 | $ 112,300 | $ 106,712 |
Cost of goods sold | 22,931 | 21,581 | 17,349 |
Gross profit | 104,427 | 90,719 | 89,363 |
Costs and expenses: | |||
Sales and marketing | 73,328 | 69,659 | 71,950 |
Research and development | 24,177 | 17,846 | 17,514 |
General and administrative | 32,338 | 26,396 | 31,305 |
Total costs and expenses | 129,843 | 113,901 | 120,769 |
Loss from operations | (25,416) | (23,182) | (31,406) |
Other (expense) income: | |||
Investment income | 93 | 605 | 2,364 |
Interest expense | (1,356) | (1,054) | (40) |
Change in fair value of derivatives | (28) | (117) | 0 |
Other expense | (278) | (38) | (53) |
Total other (expense) income, net | (1,569) | (604) | 2,271 |
Net loss | $ (26,985) | $ (23,786) | $ (29,135) |
Weighted average common shares outstanding - basic (in shares) | 41,215 | 39,967 | 39,235 |
Weighted average common shares outstanding - diluted (in shares) | 41,215 | 39,967 | 39,235 |
Loss per common share - basic (in USD per share) | $ (0.65) | $ (0.60) | $ (0.74) |
Loss per common share - diluted (in USD per share) | $ (0.65) | $ (0.60) | $ (0.74) |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Deficit |
Beginning Balance (in shares) at Dec. 31, 2018 | 38,901,000 | |||
Beginning Balance at Dec. 31, 2018 | $ 146,982 | $ 389 | $ 297,319 | $ (150,726) |
Increase (Decrease) in Stockholders' Equity | ||||
Stock-based compensation | 10,304 | 10,304 | ||
Exercise of stock options (in shares) | 689,000 | |||
Exercise of stock options and employee stock purchase plan | 4,002 | $ 7 | 3,995 | |
Net loss | (29,135) | (29,135) | ||
Ending Balance (in shares) at Dec. 31, 2019 | 39,590,000 | |||
Ending Balance at Dec. 31, 2019 | 132,153 | $ 396 | 311,618 | (179,861) |
Increase (Decrease) in Stockholders' Equity | ||||
Stock-based compensation | 8,470 | 8,470 | ||
Issuance of restricted and performance stock units (in shares) | 249,000 | |||
Issuance of restricted and performance stock units | $ 0 | $ 2 | (2) | |
Exercise of stock options (in shares) | 459,254 | |||
Shares surrendered by employees to pay tax withholdings (in shares) | (40,000) | |||
Shares surrendered by employees to pay tax withholdings | $ (670) | (670) | ||
Exercise of stock options and employee stock purchase plan (in shares) | 572,000 | |||
Exercise of stock options and employee stock purchase plan | 3,300 | $ 6 | 3,294 | |
Exercise of Oberland option net of settlement (in shares) | 248,000 | |||
Exercise of Oberland option net of settlement | 3,682 | $ 2 | 3,680 | |
Net loss | $ (23,786) | (23,786) | ||
Ending Balance (in shares) at Dec. 31, 2020 | 40,618,766 | 40,619,000 | ||
Ending Balance at Dec. 31, 2020 | $ 123,149 | $ 406 | 326,390 | (203,647) |
Increase (Decrease) in Stockholders' Equity | ||||
Stock-based compensation | 10,919 | 10,919 | ||
Issuance of restricted and performance stock units (in shares) | 254,000 | |||
Issuance of restricted and performance stock units | $ 0 | $ 2 | (2) | |
Exercise of stock options (in shares) | 783,843 | |||
Exercise of stock options and employee stock purchase plan (in shares) | 864,000 | |||
Exercise of stock options and employee stock purchase plan | $ 5,467 | $ 9 | 5,458 | |
Net loss | $ (26,985) | (26,985) | ||
Ending Balance (in shares) at Dec. 31, 2021 | 41,736,950 | 41,737,000 | ||
Ending Balance at Dec. 31, 2021 | $ 112,550 | $ 417 | $ 342,765 | $ (230,632) |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Cash flows from operating activities: | |||
Net loss | $ (26,985) | $ (23,786) | $ (29,135) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 2,721 | 1,507 | 933 |
Amortization of right-of-use assets | 1,818 | 1,800 | 1,821 |
Amortization of intangible assets | 202 | 153 | 123 |
Impairment loss on intangible assets | 0 | 0 | 104 |
Amortization of debt discount and deferred financing fees | 831 | 232 | 0 |
Loss on disposal of equipment | 0 | 3 | 0 |
Provision for bad debt | (41) | (105) | 514 |
Provision for inventory write-down | 3,314 | 2,242 | 1,887 |
Investment losses (gains) | 68 | (47) | (972) |
Change in fair value of derivatives | 28 | 117 | 0 |
Stock-based compensation | 10,919 | 8,470 | 10,304 |
Change in operating assets and liabilities: | |||
Accounts receivable | (499) | (635) | (2,136) |
Inventory | (7,478) | (910) | (3,767) |
Prepaid expenses and other | 2,435 | (2,524) | (661) |
Accounts payable and accrued expenses | (270) | 4,958 | 2,920 |
Operating lease obligations | (463) | (1,086) | (1,773) |
Cash paid for interest portion of finance leases | (2) | (3) | (4) |
Contract and other liabilities | (3) | (12) | (30) |
Net cash used in operating activities | (13,405) | (9,626) | (19,872) |
Cash flows from investing activities: | |||
Purchase of property and equipment | (27,811) | (21,905) | (4,664) |
Economic development grant proceeds | 950 | 0 | 0 |
Purchase of investments | (68,699) | (77,806) | (121,074) |
Proceeds from sale of investments | 72,500 | 83,440 | 153,571 |
Cash payments for intangible assets | (589) | (692) | (562) |
Net cash (used in) / provided by investing activities | (23,649) | (16,963) | 27,271 |
Cash flows from financing activities: | |||
Proceeds from issuance of long-term debt | 15,000 | 35,000 | 0 |
Proceeds from the paycheck protection program loan | 0 | 7,820 | 0 |
Repayment of the paycheck protection program loan | 0 | (7,820) | 0 |
Proceeds from issuance of common stock | 0 | 3,500 | 0 |
Payments for debt issuance costs | 0 | (642) | 0 |
Cash paid for debt portion of finance leases | (15) | (14) | 29 |
Proceeds from exercise of stock options and ESPP stock purchases | 5,467 | 3,300 | 4,002 |
Payments of employee tax withholdings in exchange of common stock awards | 0 | (670) | 0 |
Net cash provided by financing activities | 20,452 | 40,474 | 4,031 |
Net (decrease) increase in cash, cash equivalents, and restricted cash | (16,602) | 13,885 | 11,430 |
Cash, cash equivalents, and restricted cash, beginning of period | 55,609 | 41,724 | 30,294 |
Cash, cash equivalents, and restricted cash, end of period | 39,007 | 55,609 | 41,724 |
Supplemental disclosures of cash flow activity: | |||
Cash paid for interest, net of capitalized interest | 495 | 822 | 34 |
Supplemental disclosure of non-cash investing and financing activities: | |||
Acquisition of fixed assets in accounts payable and accrued expenses | 1,420 | 1,077 | 3,212 |
Acquisition of leasehold asset | 0 | 5,250 | 0 |
Embedded derivative associated with the long-term debt | 3,037 | 2,563 | 0 |
Obtaining a right-of-use asset in exchange for a lease liability | 1,375 | 14,259 | 26 |
Conversion of the Oberland option | 0 | 182 | 0 |
Acquisition of intangible assets in accounts payable and accrued expenses | $ 418 | $ 0 | $ 0 |
Basis of Presentation
Basis of Presentation | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | Basis of PresentationThe accompanying consolidated financial statements include the accounts of Axogen, Inc. (the “Company” or “Axogen”) and its wholly owned subsidiaries, Axogen Corporation (“AC”), Axogen Processing Corporation (“APC”) and Axogen Europe GmbH, as of December 31, 2021 and 2020 and for the three years ended December 31, 2021. The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). All intercompany accounts and transactions have been eliminated in consolidation. |
Organization and Business
Organization and Business | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Business | Organization and Business Axogen is the leading company focused specifically on the science, development, and commercialization of the technologies for peripheral nerve regeneration and repair. Axogen is passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. Axogen provides innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance ® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard ® Nerve Connector, a porcine (pig) submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard ® Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard ® Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; Avive ® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue conduit and Axotouch ® Two-Point Discriminator, used to measure the innervation density of any surface area of skin. Axogen's portfolio of products is available in the U.S., Canada, Germany, United Kingdom ("UK"), Spain, South Korea, and several other countries. Axogen suspended the market availability of Avive Soft Tissue Membrane ("Avive") effective June 1, 2021, and management continues discussion with the U.S. Food and Drug Administration (the "FDA") to determine the appropriate regulatory classification and requirements for Avive. The suspension was not based on any safety or product issues or concerns with Avive. Axogen seeks to return Avive to the market, although the Company is unable to estimate the timeframe or provide any assurance that a return to the market will be achievable. Avance Nerve Graft and Avive Soft Tissue Membrane are processed in the U.S. by Axogen pursuant to a License and Services Agreement, as amended, (the "CTS Agreement') with Community Blood Center (doing business as Community Tissue Services) ("CTS") at the CTS processing facility in Dayton, Ohio. The Axoguard product line is manufactured by Cook Biotech Incorporated ("Cook Biotech"), in West Lafayette, Indiana. The Axotouch Two-Point Discriminator is contract manufactured by Viron Technologies, LLC (doing business as Cybernetics Research Laboratories) (“CRL”) in Tucson, Arizona. CRL supplies the Axotouch Two-Point Discriminator unpackaged, and they are packaged at Axogen’s distribution facility in Burleson, Texas. In March 2020, the World Health Organization declared the outbreak of the 2019 novel coronavirus and any and all variants thereof ("COVID-19") a pandemic. The global impact of COVID-19 has had a negative effect on the global economy, disrupting the financial markets and significantly impacting the medical industry. The Company implemented certain cost mitigation initiatives in 2020 such as a reduction in pay levels, temporary suspension of tissue processing and deferral of certain projects, among other efforts. As economic activity began to normalize, the Company lifted these cost mitigation initiatives. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Cash and Cash Equivalents and Concentration The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying consolidated financial statements. The Company has not experienced any losses related to these balances; however, as of December 31, 2021, $32,238 of the cash and cash equivalents balance was in excess of Federal Deposit Insurance Corporation limits. As of December 31, 2021 and 2020, the Company had restricted cash balances of $6,251 and $6,842, respectively. The December 31, 2021 and 2020 balances both include $6,000, which represents collateral for an irrevocable standby letter of credit. Additionally, the December 31, 2021 balance includes an additional irrevocable standby letter of credit in the amount of $250 (See "Note 10 - Long-Term Debt, Net of Financing Fees"). The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows: (in thousands) December 31, December 31, Cash and cash equivalents $ 32,756 $ 48,767 Restricted cash 6,251 6,842 Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows $ 39,007 $ 55,609 Inventory Inventory is comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Axotouch Two-Point Discriminator finished goods and supplies. Inventory is valued at the lower of cost (first-in, first-out) or net realizable value. Included within Inventory at December 31, 2020 is Avive Soft Tissue Membrane ("Avive"). On May 17, 2021, the Company announced that it would suspend market availability of Avive effective June 1, 2021 pending ongoing discussions with the FDA regarding the regulatory classification of Avive. The Company recorded a write-down of Avive inventory for an amount of $1,251 recorded in cost of goods sold in the consolidated statement of operations for the year ended December 31, 2021 related to this announcement. The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. To estimate the amount of inventory that will expire prior to being distributed, the Company reviews inventory quantities on hand, historical and projected distribution levels, and historical expiration trends. The Company’s calculation of the amount of inventory that will expire prior to distribution has two components: 1) a demand or consumption-based component that compares projected distribution to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being distributed. The Company’s model assumes that inventory will be distributed on a first-in, first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that significant portions of the Company’s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written down involves significant judgments and estimates. Investments The Company invests primarily in commercial paper and U.S. government securities and classifies all investments as available-for-sale. Investments are recorded at fair value. The Company elected the fair value option ("FVO") for all of its available-for-sale investments. The FVO election results in all changes in unrealized gains and losses being included in investment income in the consolidated statements of operations. Derivative Instruments The Company reviews debt agreements for embedded features. If these features are not clearly and closely related to the debt host, they meet the definition of a derivative and require bifurcation from the host. All derivative instruments are recorded on the consolidated balance sheet at their respective fair values. The Company adjusts the carrying value of the derivative liability to fair value at each reporting date. The changes in the fair value of the derivatives are recorded in the consolidated statement of operations in the period in which they occur. The fair value of embedded derivatives are measured based on equity markets and interest rates, as well as an estimate of the Company's nonperformance risk adjustment. This estimate includes an option adjusted spread and an estimate of the Company's risk-free rate. The fair value of the embedded derivative features was determined using a probability-weighted expected return model based on four potential settlement scenarios due to (a) a 5% probability of a mandatory prepayment event of the Oberland Facility on December 31, 2023; (b) a 15% probability of a mandatory prepayment event of the Oberland Facility on March 31, 2026; (c) a 5% probability of the prepayment of the Oberland Facility at the Company’s option on December 31, 2025; and (d) a 75% probability that the Oberland Facility will be held to its scheduled maturity dates in accordance with the terms of the debt agreement. The estimated settlement value of each scenario, which would include any required make-whole payment, is then discounted to present value using a discount rate that is derived based on the initial terms of the Oberland Facility at issuance and corroborated utilizing a synthetic credit rating analysis. The calculated fair values under these four scenarios is then compared to the fair value of a plain vanilla note, with the difference reflecting the fair value of the embedded derivatives. Property and Equipment Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three When depreciable assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Intangible Assets Intangible assets are recorded at cost and include patents and patent application costs, licenses, and trademarks. Intangible assets are amortized on a straight-line basis over their estimated useful lives of seventeen Revenue Recognition The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection. Revenue is recognized when the Company has met its performance obligations pursuant to its customer contracts in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products and services to the Company’s customers. In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract. These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor’s cost. The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and therefore, the Company has determined it is appropriate to recognize revenue when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement. Determining the timing of revenue recognition for such contracts is subject to judgment, because an evaluation must be made regarding the distributor’s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company. Changes in these assessments could have an impact on the timing of revenue recognition from sales to distributors. A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of goods sold. The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing, and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers. The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company’s contracts vary; however, as a common business practice, payment terms are typically due in full within thirty To pursue its mission most effectively, the Company made a strategic decision to place its full focus on innovations within its surgical solutions portfolio. Effective November 2019, Axogen discontinued all sales of the Acroval Neurosensory and Motor Testing System. Axogen continues to provide service and support for the existing systems in the marketplace. In connection with the Acroval Neurosensory and Motor Testing System, the Company sold extended warranty and service packages to some of its customers who purchased this evaluation and measurement tool, and the prepayment of these extended warranties represent contract liabilities until the performance obligations are satisfied ratably over the term of the contract. The sale of the aforementioned extended warranty represents the only performance obligation the Company satisfies over time and creates the contract liability disclosed below. The opening and closing balances of the Company’s contract receivables and liabilities are as follows: (in thousands) Net Receivables Contract Liabilities, Current Contract Liabilities, Long-Term Opening January 1, 2020 $ 16,944 $ 14 $ 15 Closing, December 31, 2020 17,618 14 3 Increase (decrease) 674 — (12) Opening January 1, 2021 $ 17,618 $ 14 $ 3 Closing, December 31, 2021 18,158 14 — Increase (decrease) 540 — (3) Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk The Company evaluates the collectability of accounts receivable to determine the appropriate allowance for doubtful accounts. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in general and administrative expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company’s history of write-offs has not been significant. The allowance for doubtful accounts balance was $276 and $416 at December 31, 2021 and 2020, respectively. Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the credit risk. The Company also controls credit risk through credit approvals and monitoring procedures. Leases The Company adopted Accounting Standards Update (“ASU”) No. 2016-2—Leases (Topic 842), effective January 1, 2019, using the modified retrospective approach. The Company determines whether or not a contract contains a lease at the inception date and determines the lease classification, recognition, and measurement at commencement date. The Company classifies a lease based on whether the arrangement is effectively a purchase of the underlying asset. Leases that transfer the control of the underlying asset are classified as finance leases and all others are classified as operating leases. Interest and amortization expense are recognized for operating leases on a straight-line basis. If a change to the lease term leads to a reassessment of the lease classification and remeasurement, assumptions such as the discount rate and variable rents based on a rate or index will be updated as of the remeasurement date. If an arrangement is modified, the Company will reassess whether the arrangement contains a lease. Any subsequent changes in lease payments are recognized when incurred, unless the change requires a remeasurement of the lease liability. The Company made an accounting policy election to not recognize right-of-use assets and lease obligations that arise from short-term leases, which are defined as leases with a lease term of 12 months or less at the lease commencement date. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company leases office space, medical lab and research space, a distribution center, a tissue processing center, and equipment. Certain of the Company's leases include options for the Company to extend the lease term. None of the options were reasonably certain of exercise, and therefore are not included in the measurement of lease obligations and right-of-use assets. Certain of the Company's lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Net Loss Per Share Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested stock options, restricted stock units (“RSUs”), and performance stock units (“PSUs”). Due to net losses for the years ended December 31, 2021, 2020 and 2019, basic and diluted net loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive. Research and Development Costs Research and development costs are expensed as incurred and were $24,177, $17,846 and $17,514 for the years ended December 31, 2021, 2020 and 2019, respectively. Stock-Based Compensation The Company measures all stock-based compensation awards, including stock options, RSUs, and PSUs at, or above, the fair market value of the Company's common stock on the date of grant. The Company estimates the fair value of each option award on the date of grant using a multiple-point Black-Scholes option-pricing model ("Black-Scholes") which uses a weighted average of historical volatility and peer company volatility. The Company’s determination of fair value is affected by the Company’s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the awards. The Company determines the expected life of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The expense has been reduced for forfeitures as they occur. The Company estimates the fair value of RSUs based upon the grant date closing market price of the Company’s common stock. With respect to PSUs, the number of shares that vest and are issued to the recipient is based upon the Company’s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company’s closing stock price on the grant date and its estimate of achieving such performance targets. For further discussion and disclosures, see "Note 11 - Stock-Based Incentive Plans." The Company also has an employee stock purchase plan that is available to all eligible employees as defined by the plan document. Under the Axogen 2017 Employee Stock Purchase Plan ("2017 ESPP"), eligible employees may acquire shares of the Company’s common stock through payroll deductions at a discount to market price. The Company estimates the number of shares to be purchased under the 2017 ESPP at the beginning of each purchase period based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model and records estimated compensation expense during the period. Expense is adjusted at the time of stock purchase. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Management believes the critical accounting estimates relating to inventory, derivative instruments, and stock-based compensation affect the Company's more significant judgments and estimates used in the preparation of the Company’s consolidated financial statements. Actual results could differ materially from those estimates. Recent Accounting Pronouncements In November 2021, the Financial Accounting Standards Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832 ) , Disclosures by Business Entities about Government Assistance, which requires business entities to provide certain annual disclosures when they have received government assistance and use a grant or contribution accounting model by analogy to other accounting guidance (e.g., a grant model under International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance ). The disclosures should provide the nature of the transaction, including the significant terms and conditions of the transaction, the accounting policies used to account for the transaction, and the dollar amounts by line item on the financial statements that are affected by the transaction. The adoption of this ASU will be required beginning with the Company's Annual Report on Form 10-K for the year ending December 31, 2022, on either a prospective basis or retrospective basis. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. Recently Adopted Accounting Pronouncements Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which was intended to simplify the accounting for income taxes by removing certain exceptions to the general rules found in Topic 740 - Income Taxes . The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. Effective January 1, 2021, the Company adopted ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs . The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures. |
Inventory
Inventory | 12 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Inventory | Inventory Inventory consists of the following: (in thousands) December 31, December 31, Finished goods $ 11,011 $ 8,876 Work in process 813 751 Raw materials 4,869 2,902 Inventory $ 16,693 $ 12,529 The provision for inventory write-down was $3,314, $2,242 and $1,887 for the years ended December 31, 2021, 2020 and 2019, respectively. The provision for inventory write-down for the year ended December 31, 2021 includes the Avive write-down of $1,251. |
Fair Value Measurement
Fair Value Measurement | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurement | Fair Value MeasurementThe Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Cash equivalents, investments and derivative instruments are recorded at fair value on a recurring basis. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company has elected the FVO for its investments. Unrealized gains and losses on investments have been reported in investment income in the consolidated statements of operations at each reporting date. The Company classifies cash equivalents (consisting of money market funds) and investments in U.S. government securities as Level 1 within the fair value hierarchy. Investments in commercial paper and corporate bonds are classified as Level 2 within the fair value hierarchy. On June 30, 2020, the Company entered into the Oberland Facility (see "Note 10 - Long-Term Debt, Net of Financing Fees") and obtained the first tranche of $35,000 at closing. On June 30, 2021, the second tranche of $15,000 was drawn down by the Company. The Company determined that the term debt instrument included certain embedded features that required separate accounting identified as the Debt Derivative Liabilities and that the equity contract (the “Common Stock Derivative Option Liability”) entered into concurrently were required to be classified as liabilities and recorded at fair value, requiring Level 3 fair value measurements. The Common Stock Derivative Option Liability was settled on December 10, 2020 (see "Note 10 - Long-Term Debt, Net of Financing Fees"). The Debt Derivative Liabilities are measured using a ‘with and without’ valuation model to compare the fair value of the Oberland Facility including the identified embedded derivative features and the fair value of a plain vanilla note with the same terms. The fair value of the Oberland Facility including the embedded derivative features was determined using a probability-weighted expected return model based on four potential settlement scenarios for the Oberland Facility due to (a) a 5% probability of a mandatory prepayment event of the Oberland Facility on December 31, 2023; (b) a 15% probability of a mandatory prepayment event of the Oberland Facility on March 31, 2026; (c) a 5% probability of the prepayment of the Oberland Facility at the Company’s option on December 31, 2025; and (d) a 75% probability that the Oberland Facility will be held to its scheduled maturity dates in accordance with the terms of the debt agreement. The estimated settlement value of each scenario, which would include any required make-whole payment (see "Note 10 - Long-Term Debt, Net of Financing Fees"), is then discounted to present value using a discount rate that is derived based on the initial terms of the Oberland Facility at issuance and corroborated utilizing a synthetic credit rating analysis. The significant inputs that are included in the valuation of the Debt Derivative Liability - first tranche include: December 31, 2021 December 31, 2020 Input Remaining term (years) 5.5 6.5 Maturity date June 30, 2027 June 30, 2027 Coupon rate 9.50% 9.50% Revenue participation payments Maximum each year Maximum each year Discount rate 10.72% 1 8.70 % 1 Probability of mandatory prepayment before 2024 5.0% 1 5.0% 1 Estimated timing of mandatory prepayment event before 2024 December 31, 2023 1 December 31, 2023 1 Probability of mandatory prepayment 2024 or after 15.0% 1 15.0% 1 Estimated timing of mandatory prepayment event 2024 or after March 31, 2026 1 March 31, 2026 1 Probability of optional prepayment event 5.0% 1 5.0% 1 Estimated timing of optional prepayment event December 31, 2025 1 December 31, 2025 1 1 Represents a significant unobservable input. The significant inputs that are included in the valuation of the Debt Derivative Liability - second tranche include: December 31, 2021 Input Remaining term (years) 6.5 Maturity date June 30, 2028 Coupon rate 9.50% Revenue participation payments Maximum each year Discount rate 13.21 % (1) Probability of mandatory prepayment before 2024 5.0% (1) Estimated timing of mandatory prepayment event before 2024 December 31, 2023 (1) Probability of mandatory prepayment 2024 or after 15.0% (1) Estimated timing of mandatory prepayment event 2024 or after March 31, 2026 (1) Probability of optional prepayment event 5.0% (1) Estimated timing of optional prepayment event December 31, 2025 (1) 1 Represents a significant unobservable input. The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020: (in thousands) Level 1 Level 2 Level 3 Total December 31, 2021 Assets: Money market funds $ 22,012 $ — $ — $ 22,012 U.S. government securities 12,081 — — 12,081 Commercial paper — 39,249 — 39,249 Total assets $ 34,093 $ 39,249 $ — $ 73,342 Liabilities: Debt derivative liabilities $ — $ — $ 5,562 $ 5,562 Total liabilities $ — $ — $ 5,562 $ 5,562 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 23,044 $ — $ — $ 23,044 U.S. government securities 12,123 — — 12,123 Corporate bonds — 6,408 — 6,408 Commercial paper — 36,668 — 36,668 Total assets $ 35,167 $ 43,076 $ — $ 78,243 Liabilities: Debt derivative liability $ — $ — $ 2,497 $ 2,497 Total liabilities $ — $ — $ 2,497 $ 2,497 The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows: (in thousands) Common Stock Derivative Option Liability Debt Derivative Liabilities Balance, December 31, 2019 $ — $ — Acquired 175 2,387 Change in fair value included in net loss 7 110 Settlement (182) — Balance, December 31, 2020 — 2,497 Acquired — 3,037 Change in fair value included in net loss — 28 Balance, December 31, 2021 $ — $ 5,562 The fair value of cash, restricted cash, accounts receivable, accounts payable and accrued expenses approximates the carrying values because of the short-term nature of these instruments. The Oberland Facility is classified as Level 3 within the fair value hierarchy. The carrying value and fair value of the Oberland Facility were $45,325 and $52,605 at December 31, 2021, respectively, and $32,623 and $36,855 at December 31, 2020, respectively. |
Prepaid Expense and Other
Prepaid Expense and Other | 12 Months Ended |
Dec. 31, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Prepaid Expense and Other | Prepaid Expenses and Other Prepaid expenses and other consist of the following: (in thousands) December 31, 2021 December 31, 2020 Prepaid insurance $ — $ 2,596 Stock option receivable 3 2 Litigation receivable 23 23 Prepaid events 54 203 Prepaid marketing 620 587 Prepaid software license 215 220 Prepaid professional fees 207 251 Other prepaid items 739 414 Prepaid expenses and other $ 1,861 $ 4,296 The policy year for the Company's insurance runs on a calendar year and as such, a significant portion of the policy payment is made at the beginning of the new year and amortized to expense throughout the remaining year. For the year ended December 31, 2020, the insurance premium was paid prior to year-end, resulting in a prepaid balance of $2,596. |
Property and Equipment
Property and Equipment | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | Property and Equipment , Net Property and equipment, net consist of the following: (in thousands) December 31, December 31, Furniture and equipment $ 5,100 $ 2,334 Leasehold improvements 14,952 12,983 Processing equipment 3,984 2,634 Land 731 731 Projects in process 45,660 24,541 Property and equipment, at cost 70,427 43,223 Less: accumulated depreciation and amortization (7,546) (4,825) Property and equipment, net $ 62,881 $ 38,398 Depreciation expense was $2,721, $1,507 and $933 for the years ended December 31, 2021, 2020 and 2019, respectively. The significant increase in projects in process is related to the Company's Axogen Processing Center ("APC Facility") (See "Note 14 - Commitments and Contingencies"). |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Intangible Assets, Net Intangible assets consist of the following: December 31, 2021 December 31, 2020 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortizable intangible assets: Patents $ 2,469 $ (234) $ 2,235 $ 1,496 $ (139) $ 1,357 License agreements 1,101 (852) 249 1,093 (745) 348 Total amortizable intangible assets 3,570 (1,086) 2,484 2,589 (884) 1,705 Unamortized intangible assets: Trademarks 375 — 375 349 — 349 Total intangible assets $ 3,945 $ (1,086) $ 2,859 $ 2,938 $ (884) $ 2,054 License agreements are being amortized over periods ranging from seventeen As of December 31, 2021, future amortization of patents and license agreements are as follows: Year Ending December 31, (in thousands) 2022 $ 233 2023 207 2024 130 2025 130 2026 129 Thereafter 1,655 Total $ 2,484 License Agreements The Company has entered into multiple license agreements with the University of Florida Research Foundation and the University of Texas at Austin (together, the “License Agreements”). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the U.S. and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below: • The Company pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $13 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when the Company pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%; • If the Company sub-licenses technologies covered by the License Agreements to third parties, the Company would pay a percentage of sub-license fees received from the third party to the licensor. Currently, the Company does not sub-license any technologies covered by the License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sub-licensee fees for its own use of the technologies; • The Company reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and • Currently, under the University of Texas at Austin’s agreement, the Company would owe a $15 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. A milestone fee to the University of Florida Research Foundation of $2 is due if the Company receives FDA approval of its Avance Nerve Graft, a milestone fee of $25 is due upon the first commercial use of certain licensed technology to provide services to manufacture products for third parties and a milestone fee of $10 is due upon the first use to manufacture products that utilize certain technology that is not currently incorporated into the Company's products. Royalty fees were $2,715, $2,289 and $2,119 for the years ended December 31, 2021, 2020 and 2019, respectively, and are included in sales and marketing expense in the accompanying consolidated statements of operations. |
Accounts Payable and Accrued Ex
Accounts Payable and Accrued Expenses | 12 Months Ended |
Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Expenses | Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following: (in thousands) December 31, December 31, Accounts payable $ 5,923 $ 4,597 Accrued expenses 6,863 3,778 Accrued compensation 9,673 13,593 Accounts payable and accrued expenses $ 22,459 $ 21,968 |
Long-Term Debt, Net of Financin
Long-Term Debt, Net of Financing Fees | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Long-Term Debt, Net of Financing Fees | Long-Term Debt , Net of Financing Fees Long-term debt, net of financing fees consists of the following: (in thousands) December 31, 2021 December 31, 2020 Oberland Facility - first tranche $ 35,000 $ 35,000 Oberland Facility - second tranche 15,000 — Less - unamortized debt discount and deferred financing fees (5,179) (2,973) Long-term debt, net of financing fees $ 44,821 $ 32,027 Oberland Facility On June 30, 2020, the Company entered into a seven-year financing agreement with Oberland Capital (the “Oberland Facility”) and obtained the first tranche of $35,000 at closing. On June 30, 2021, the second tranche of $15,000 was drawn down by the Company. The financing costs for this facility were $642 and were recorded as a contra liability to the debt facility. As of December 31, 2021, the Company has paid all of the financing costs. The Oberland Facility requires quarterly interest payments for seven years. Interest is calculated as 7.5% plus the greater of the London Interbank Offered Rate ("LIBOR") or 2.0% (9.5% as of December 31, 2021). Each tranche of the Oberland Facility has a term of seven years from the date of issuance (with the first tranche issued on June 30, 2020 maturing on June 30, 2027 and the second tranche issued on June 30, 2021 maturing on June 30, 2028). In connection with the Oberland Facility, the Company entered into a revenue participation agreement with Oberland Capital, which provides that, among other things, a quarterly royalty payment as a percentage of the Company’s net revenues, up to $70 million in any given year, subject to certain limitations set forth therein, during the period commencing on the later of (i) April 1, 2021 and (ii) the date of funding of a tranche of the loan, and ending on the date upon which all amounts owed under the Oberland Facility have been paid in full (the “Revenue Participation Agreement”). Royalty payments commenced on September 30, 2021. This royalty structure results in approximately 1.0% per year of additional interest payments on the outstanding loan amount. The Company recorded $646 as interest expense for this Revenue Participation Agreement for the year ended December 31, 2021. The Company pays the quarterly debt interest on the last day of the quarter, and for the years ended December 31, 2021 and 2020, paid $4,103 and $1,709, respectively, to Oberland Capital. The Company capitalized interest of $4,277 and $997 for the years ended December 31, 2021 and 2020, respectively, towards the costs to construct and retrofit its APC Facility in Vandalia, OH (See "Note 14 - Commitments and Contingencies"). To date, the Company has capitalized interest of $5,274 related to this project. The capitalized interest is recorded as part of property and equipment in the consolidated balance sheets. Additionally, Oberland Capital had the right to purchase up to $3,500 worth of the Company's common stock from the Company in one transaction at any time after closing of the Oberland Facility until the later of (i) the date all amounts due under the Oberland Facility are repaid and (ii) June 30, 2027 (the “Oberland Option”). The purchase price of the common stock was calculated based on the 45-day moving average of the closing stock price on the day prior to the purchase. On December 10, 2020, Oberland Capital exercised in full its option under the Oberland Option. The exercise price was determined to be $14.13, resulting in gross proceeds to the Company of $3,500 and the issuance of 247,699 shares to TPC Investments II LP, a wholly owned subsidiary of Oberland Capital. In conjunction with the issuance of the shares, Oberland Capital received certain protective rights (including protection from down-round stock issuances) for a period of one year subsequent to the issuance. These rights expired on December 10, 2021. The amounts outstanding under the Oberland Facility may be accelerated upon certain events, including: (a) required mandatory prepayments upon an asset sale; (b) in the event the Company is subject to (i) any litigation brought by a Governmental Authority (as defined in the Oberland Facility) including intervention after litigation is commenced by a Person (as defined in the Oberland Facility), or (ii) any final administrative action by a Governmental Authority, in each case arising out of or in connection with any of the Company’s registry studies, payments made to doctors or training activities with respect to healthcare professionals (excluding certain final administrative actions that have been fully and finally resolved by the parties pursuant to a settlement agreement) or (c) upon the occurrence of an event of default (either automatically or at the option of Oberland Capital depending on the nature of the event). In addition, the Company has the right to prepay any amounts outstanding under the Oberland Facility. Upon maturity or upon such earlier repayment of the Oberland Facility, the Company will repay the principal balance and provide a make-whole payment calculated to generate an internal rate of return to Oberland Capital equal to 11.5%, less the total of all quarterly interest and royalty payments previously paid to Oberland Capital. See Note 14 - Commitments and Contingencies for further information. Upon the occurrence of an event of default, the interest rate incurred on amounts outstanding under the Oberland Facility will be increased by 4%. The Oberland Facility includes a financial covenant requiring the Company to achieve revenue targets of $8,750 for the third and four quarters of 2020, $17,500 for the first and second quarters of 2021 and $20,000 for each quarter thereafter. As of December 31, 2021, the Company was in compliance with all the covenants. In the event of a failure to meet such covenant the Company may avoid a default by electing to be subject to a liquidity covenant and meeting all of the obligations required by such covenant. Specifically, the liquidity covenant provides that the Company must maintain on deposit in a cash collateral account an amount not less than 1.1 times the aggregate outstanding principal balance of all outstanding loan amounts. The borrowings under the Oberland Facility are secured by substantially all of the assets of the Company. Accounting Considerations The Company assessed the accounting impact of the Oberland Facility and the related agreements entered into with Oberland Capital. The Company concluded that the Oberland Facility and the Revenue Participation Agreement should be assessed on a combined unit of account basis (with the Revenue Participation Agreement being considered as an embedded feature with the Oberland Facility), and that the Oberland Option should be considered as a separate freestanding instrument for analysis purposes. In relation to the Oberland Facility and Revenue Participation Agreement, the Company assessed the identified embedded features to determine if they would require separate accounting. In performing this assessment, the Company concluded the following embedded features met the definition of a derivative and would not be considered clearly and closely related to the debt instrument, requiring separate accounting as bifurcated derivatives: • Mandatory prepayments upon an asset sale or litigation involving the government, including the make-whole payment (put rights) • Optional or automatic prepayment upon an event of default (put rights) • Payments under the Revenue Participation Agreement (contingent interest feature) • Additional interest upon events of default (contingent interest feature) The Company considered these separable embedded features on a combined basis as a single derivative feature. The Company estimated the fair value of these features as $2,387 as of the date of issuance of the Oberland Facility (see "Note 5 - Fair Value Measurement") and recorded this value as a debt derivative liability. As a result of the second tranche draw on June 30, 2021, the Company recorded an additional derivative and estimated the fair value to be $1,961, along with an increase of $1,076 related to the first tranche derivative. In relation to the Oberland Option, the Company concluded that the equity contract met the definition of a derivative and did not qualify for an exception from derivative accounting. As such, the Company concluded that the Oberland Option should be classified as a liability. The Company estimated the fair value of the Common Stock Derivative Option Liability as $175 as of the date of issuance of the Oberland Facility (see "Note 5 - Fair Value Measurement") and recorded this value as the Common Stock Derivative Option Liability. The Common Stock Derivative Option Liability was settled on December 10, 2020. Other Long-Term Debt On April 23, 2020, the Company received a Small Business Administration (“SBA”) loan under the Paycheck Protection Program (“PPP”) in the amount of $7,820. The loan was obtained pursuant to the original guidance of the SBA to preserve positions in the Company by providing necessary economic relief during this period of reduced surgical procedures because of the negative business effects of COVID-19. The Company believed it correctly applied for the loan, met the initial intent of the PPP program to preserve jobs and believed it complied with the representations provided in the loan documents. However, subsequent to obtaining the loan, the U.S. Treasury Department issued guidance, which the Company believed contradicted the original intent and language of the PPP, providing that public companies are unlikely to be able to meet the standards for receiving the PPP loan. As a result of this change, the Company believed it was in its best business interests to repay the loan and did so on May 5, 2020. Other Credit Facilities |
Stock-Based Incentive Plans
Stock-Based Incentive Plans | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Equity Compensation Plans | Stock-Based Incentive Plans The Company maintains two stock-based incentive plans: the Axogen, Inc. 2019 Amended and Restated Long-Term Incentive Plan, as amended ("2019 Plan") and the Axogen 2017 Employee Stock Purchase Plan (“2017 ESPP”). Long-Term Incentive Plan At the 2019 Annual Meeting of Shareholders held on August 14, 2019, the shareholders approved the 2019 Plan, which allows for the award of incentive stock options, non-qualified stock options, PSUs and RSUs to employees, directors, and consultants. Awards under the 2019 Plan are priced at, or above, the fair market value of the Company's common stock on the date of grant. At the 2021 Annual Meeting of Shareholders held on May 10, 2021, the shareholders approved an additional 2,500,000 shares to be allocated for issuance under the 2019 Plan. The number of shares of common stock authorized for issuance under the 2019 Plan is (a) 5,885,482 shares, comprised of (i) 5,500,000 new authorized shares and (ii) 385,482 unallocated shares of common stock available for issuance as of August 14, 2019 pursuant to the Company’s 2010 Stock Incentive Plan, as amended and restated (the “2010 Plan”), that were not then subject to outstanding awards; plus (b) shares under the 2010 Plan and the 2019 Plan that are cancelled, forfeited, expired, unearned or settled in cash, in any such case that does not result in the issuance of common stock. No future awards will be made under the 2010 Plan. As of December 31, 2021, 3,630,823 shares of common stock were available for issuance under the 2019 Plan. The Company recognized stock-based compensation expense, which consisted of compensation expense related to employee stock options, PSUs and RSUs based on the value of stock-based payment awards that are ultimately expected to vest during the period and stock-based compensation expense related to the 2017 ESPP of $10,919, $8,470 and $10,304 for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, there was $19,502 of unrecognized compensation costs related to non-vested stock options and restricted stock awards. This cost is expected to be recognized over a weighted-average period of 2.09 years for stock options and 2.04 years for restricted stock awards. Stock Options The options granted to employees prior to July 1, 2017 typically vest 25% one year after the grant date and 12.5% every six months thereafter for the remaining three-year period until fully vested after four years. The options granted to employees after July 1, 2017 typically vest 50% two years after the grant date and 12.5% every six months thereafter for the remaining two-year period until fully vested after four years. The options granted to directors and certain options granted from time to time to certain executive officers have vested ratably over three years or 25% per quarter over one year. Options typically have terms ranging from seven A summary of the stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding at December 31, 2019 3,420,181 $ 12.69 5.70 $ 26,074 Granted 663,098 $ 9.29 Forfeited (107,541) $ 19.71 Exercised (459,254) $ 5.36 Outstanding at December 31, 2020 3,516,484 $ 12.79 5.93 $ 25,718 Granted 656,398 $ 20.00 Forfeited (194,301) $ 17.02 Exercised (783,843) $ 5.89 Outstanding at December 31, 2021 3,194,738 $ 15.65 6.45 $ 2,236 Exercisable at December 31, 2021 1,865,381 $ 15.08 4.95 $ 1,932 The exercise price per share of each option is equal to the fair market value of the underlying share on the date of grant. For the years ended December 31, 2021, 2020 and 2019, $5,467, $3,300 and $4,002, respectively, in cash proceeds were included in the Company’s consolidated statements of cash flows as a result of the exercise of stock options and Employee Stock Purchase Plan stock purchases. The intrinsic value of equity awards exercised during the years ended December 31, 2021, 2020 and 2019 was $14,167, $5,595 and $9,553, respectively. The following weighted-average assumptions were used for stock options granted during the years ended December 31: Year Ended December 31, 2021 2020 2019 Expected term (in years) 5.88 5.88 5.76 Expected volatility 58.38 % 58.46 % 54.97 % Risk free rate 1.02 % 0.49 % 1.71 % Expected dividends — % — % — % Restricted and Performance Stock Units RSUs granted to employees have a requisite service period of four years. The RSUs granted to directors and certain RSUs granted from time to time to certain executive officers have a requisite service period of three years, while certain of these RSUs have a requisite service period of one year. The Company expenses the fair value of RSUs on a straight-line basis over the requisite service period. A summary of the status of non-vested RSUs and PSUs as of December 31, 2021 and 2020 and the changes during the years then ended are as follows: Outstanding Restricted and Performance Stock Units Stock Units Weighted Weighted Average Remaining Vesting Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2019 1,113,697 $ 21.62 2.26 $ 19,800 Granted 1,008,869 $ 9.57 Released (247,333) $ 19.66 Forfeited (92,328) $ 18.64 Outstanding at December 31, 2020 1,782,905 $ 15.23 1.83 $ 31,825 Granted 898,264 $ 20.35 Released (253,881) $ 17.50 Forfeited (696,513) $ 13.00 Outstanding at December 31, 2021 1,730,775 $ 18.45 1.51 $ 19,633 The total fair value of restricted stock vested during the years ended December 31, 2021, 2020 and 2019 was $4,481, $3,811 and $1,467, respectively. The Company issues registered shares of common stock to satisfy stock option exercises and restricted stock grants. Performance Stock Units The Company estimates the fair value of the PSUs based on its closing stock price at the time of grant and its estimate of achieving such performance target and records compensation expense as the milestones are achieved. PSUs generally have a requisite service period of three years and are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses their fair value over the requisite service period. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense will be adjusted based upon the Company’s estimate of achieving such performance target. The number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on the actual performance metrics as set forth in the applicable PSU award agreement. The amount actually awarded will be based upon achievement of the performance measures. On December 18, 2017, December 27, 2018 and December 17, 2019, the Compensation Committee of the Board of Directors approved PSU awards to certain employees related to their work on the Company’s Biologics License Application ("BLA"). The PSU awards consist of a targeted total award of 378,863 shares, of which 298,587 shares remain available as of December 31, 2021. The number of shares is allocated to certain milestones related to the BLA submission to and approval by the FDA. These awards are expected to vest beginning when the BLA is submitted to the FDA, which is not expected to be until 2023. The performance measure is based upon achieving each of the specific milestones and will vest 50% upon achieving each of the milestones and 50% one year later. No expense has been recognized on these awards yet. On December 18, 2017, the Compensation Committee of the Board of Directors approved PSU awards of 114,700 shares tied to 2019 revenue. The award was issued at 72.3% of achievement and therefore, 27.7% of the stock compensation expense or $536 relating to this grant, was forfeited or reversed in the first quarter of 2020. On December 27, 2018, the Compensation Committee of the Board of Directors approved PSU awards of 130,400 tied to 2020 revenue. As a result of COVID-19, it was determined these PSU awards would not be granted and therefore stock compensation related to these awards of $1,161 was forfeited in 2020. No expense related to these awards was recorded in 2021 and the awards were forfeited. On March 16, 2020, the Compensation Committee of the Board of Directors approved PSU awards of 357,000 shares tied to 2021 revenue. In June 2020, the Company concluded that the performance metrics relating to these awards with performance metrics tied to 2021 revenue were no longer probable and therefore stock compensation expense related to these awards of $340 was reversed in 2020. Subsequently, in the fourth quarter of 2020, it became probable that the Company would achieve 50% of these performance metrics and therefore adjusted stock compensation expense. In the third quarter of 2021, it was determined that the performance metrics tied to 2021 revenue were no longer probable; therefore, stock compensation expense related to these awards of $804 was reversed in 2021 and the awards were forfeited. On July 17, 2020, the Compensation Committee of the Board of Directors approved PSU awards of 144,300 shares tied to 2020 revenue. These awards were granted in mid-year with certain revenue targets adjusted for the impact of COVID-19. These 2020 awards granted in July reached 110% achievement of revenue targets. On March 16, 2021, the Compensation Committee of the Board of Directors approved PSU awards of 332,200 shares tied to 2022 revenue, with a payout ranging from 0% to 200% upon achievement of specific revenue goals. In the fourth quarter of 2021, it was determined that the performance metrics tied to 2022 revenue were no longer probable; therefore, stock compensation expense related to these awards of $1,831 was reversed in 2021. At December 31, 2021, the total future stock compensation expense related to non-vested performance awards is expected to be $484 for those awards issued on December 18, 2017 and July 17, 2020. Future stock compensation expense has not been calculated on those awards for which expensing has not yet begun which include the BLA awards and the awards tied to 2022 revenue. Employee Stock Purchase Plan The 2017 ESPP allows eligible employees to acquire shares of the Company's common stock through payroll deductions at a discount to market price (currently15.00%) of the lesser of the closing price of the Company’s common stock on the first day or last day of the offering period. The offering period is currently 6 months and the offering prices are subject to change. Participants may not purchase more than $25 of the Company’s common stock in a calendar year. Stock-based compensation expense related to the 2017 ESPP, included in total stock-based compensation expense, was $401, $493 and $744 for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, there were 600,000 shares of the Company's common stock authorized for issuance under the 2017 ESPP and 223,678 shares remain available for issuance. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates. Deferred tax assets and deferred tax liabilities are as follows: (in thousands) December 31, December 31, Deferred tax assets: Net operating loss carryforwards $ 47,021 $ 42,317 Inventory write-down 653 397 Depreciation — Interest limitation 453 115 Allowance for doubtful accounts 70 106 Lease obligations 5,736 5,551 Stock-based compensation 3,985 3,218 Research and development credit 6 — Total deferred tax assets 57,924 51,704 Deferred tax liabilities: Depreciation (692) (1,145) Amortization (116) (34) Right-of-use assets (3,861) (4,004) Contract liabilities (4) (4) Total deferred tax liabilities (4,673) (5,187) Net deferred tax assets $ 53,251 $ 46,517 Valuation allowance $ (53,251) $ (46,517) A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that a portion or none of the deferred tax assets will be realized. As of December 31, 2021 and 2020, management assessed the realizability of deferred tax assets. After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management determined that a full valuation allowance was necessary as of December 31, 2021 and 2020. The valuation allowance increased by $6,734 and $6,585 during 2021 and 2020, respectively, primarily as a result of the increase in the net operating loss carryforward in each year. The difference between the financial statement income tax benefit and the income tax benefit using statutory rates is primarily due to the valuation allowance. The Company’s effective income tax rate differs from the statutory federal income tax rate for the years ended December 31, 2021, 2020 and 2019 as follows: Year Ended December 31, 2021 2020 2019 Federal tax rate 21.0 % 21.0 % 21.0 % State taxes - net of Federal benefit 5.1 7.3 4.1 Permanent items and other deductions (1.4) (0.6) (4.3) Valuation allowance (24.7) (27.7) (20.8) Effective income tax rate — % — % — % The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the consolidated balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. As of December 31, 2021, the Company had tax-effected net operating loss carryforwards of $47,021 to offset future taxable income. Net operating losses incurred in tax years beginning on or after January 1, 2018 are carried forward indefinitely. Net operating losses incurred in tax years prior to January 1, 2018 are subject to a twenty year carryforward before expiring. A portion of the net operating loss carryforwards may expire due to limitations imposed by Section 382 of the Internal Revenue Code. Future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership. The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business, the Company is subject to examination by taxing authorities throughout the U.S. These examinations could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state, and local laws. The Company’s remaining open tax years subject to examination by federal tax authorities include the years ended December 31, 2018 through 2021. The Company's remaining open tax years subject to examination by state and foreign tax authorities include the years ended December 31, 2017 through 2021. However, for tax years 2004-2017, federal and state taxing authorities may examine and adjust loss carryforwards in the years in which those loss carryforwards are ultimately utilized. Legislation enacted in 2018, titled the Tax Cuts and Jobs Act of 2017, subjects a U.S. shareholder to tax on global intangible low-taxed income (“GILTI”) earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income , states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. The Company has no recorded income tax expense or income tax benefit for the years ended December 31, 2021, 2020 and 2019 due to the generation of net operating losses, the benefits of which have been fully reserved. The Company does not believe there are any additional tax refund opportunities currently available. |
Employee Benefit Plan
Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2021 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plan | Retirement PlanThe Company sponsors the Axogen 401(k) plan (the "401(k) Plan"), a defined contribution plan covering substantially all employees of the Company. All full-time employees who have attained the age of 18 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 3% on the first 3% of the employee’s annual salary and 1% on the next 2% of the employee’s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately. Employer contributions to the 401(k) Plan were $1,346, $1,141 and $988 for the years ended December 31, 2021, 2020 and 2019, respectively. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Leases The Company and Alachua Copeland Park Investments, LLC, a Florida limited liability company (as successor in interest to Ology Bioservices Holdings, LLC, a Delaware limited liability company, who was successor in interest to SNH Medical Office Properties Trust), are parties to a lease dated February 6, 2007, as amended (the “Primary Lease”). Pursuant to the Primary Lease, the Company leases an approximately 19,000 square foot corporate headquarters facility in Alachua, Florida. On July 13, 2021, the Company entered into a sixth amendment to the Primary Lease to extend the term of the Primary Lease to October 31, 2026. The Company recorded a right-of-use asset of $1,335 and a lease liability of $1,370 related to this extension. The Company and Cousins Heights Union, LLC, a Georgia limited liability company (as successor in interest to Heights Union, LLC), are parties to a lease of 75,000 square feet of office and lab space in Tampa, Florida (the "Heights Agreement"). Pursuant to the Heights Agreement, the Company uses the leased premises for general office, medical laboratory, training, and meeting purposes. In September 2020, the Company began occupying the space. The lease includes a $5,250 lessor allowance to be used towards the hard and soft costs of the tenant improvements and has been treated as an incentive. The Company incurred the cost of any tenant improvement in excess of this allowance. The Company concluded that it is the accounting owner of the tenant improvements and therefore, the lease incentive is accounted for as a reduction of the right-of-use asset and is recognized on the consolidated balance sheet separate from the right-of-use asset as leasehold improvements. The improvements will be amortized over the life of the lease, which was determined to be the shorter of the useful life of the improvements or the lease term. The Company determined the commencement date of the lease was August 28, 2020 and valued the lease using a 10.6% incremental borrowing rate. The Company recorded a right-of-use asset of $13,323 and a lease liability of $18,573 for this lease as of the commencement date. On July 12, 2021, the Company entered into the first amendment (the "First Amendment") to the Heights Agreement. The First Amendment revises the commencement date of the Heights Agreement to mean October 30, 2020 and revises the termination date of the Heights Agreement to be October 31, 2034. Pursuant to the First Amendment, the Company was entitled to an additional 1.5 months of free rent periods. The Company and Ja-Cole L.P. are parties to a lease dated April 21, 2015, as amended (the "Primary Lease"), and a lease dated October 1, 2020, pursuant to which the Company leases approximately 17,500 square feet in total (the “Burleson Facility”) in Burleson, Texas. On January 27, 2022, the Company and Ja-Cole L.P. amended the Primary Lease for 15,000 square feet of the Burleson Facility to revise the commencement date of the lease to mean May 1, 2022 and the termination date of the lease to be April 30, 2027. The Burleson Facility houses raw material storage and product distribution while allowing same day order fulfillment for both the east and west coasts of the U.S. On August 6, 2015, the Company entered into the CTS Agreement with Community Blood Center (doing business as Community Tissue Services) (“CTS”), in Dayton, Ohio, an FDA registered tissue establishment. Processing of the Avance Nerve Graft pursuant to the CTS Agreement began in February 2016. The CTS Agreement initially had a five-year term ending August 31, 2020. After three previous term extensions, on February 22, 2021, the CTS Agreement was further amended to extend the term of the agreement to December 31, 2023. Under the CTS Agreement, the Company pays CTS a facility fee for use of clean room/manufacturing, storage, and office space, which the Company accounts for as an embedded lease in accordance with Accounting Standards Codification 842, Leases . The components of total lease expense for the years ended December 31, 2021, 2020 and 2019 were as follows: Year Ended December 31, (in thousands) 2021 2020 2019 Finance lease costs Amortization of right-of-use assets $ 22 $ 22 $ 22 Interest on lease obligations 2 3 4 Operating lease costs Operating lease costs 4,326 2,777 1,910 Short-term lease costs 10 116 41 Variable lease costs 744 18 17 Total lease expense $ 5,104 $ 2,936 $ 1,994 The short-term lease costs shown above reasonably reflect the Company’s ongoing short-term lease commitments. No new short-term leases were entered into in 2021. The increase in variable lease costs is due to additional rent comprised primarily of operating costs related to the Tampa office and lab space. Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 was as follows: (in thousands) December 31, December 31, Operating Leases Operating lease right-of-use assets $ 15,193 $ 15,614 Current maturities of long-term lease obligations $ 1,825 $ 846 Long-term lease obligations $ 20,794 $ 20,864 Finance Leases Finance lease right-of-use assets $ 42 $ 64 Current maturities of long-term lease obligations $ 9 $ 17 Long-term lease obligations $ 4 $ 13 Other information related to leases was as follows ($ in thousands): Year Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of operating lease obligations $ 1,537 $ 1,913 Right-of-use assets obtained in exchange for new finance lease obligations $ — $ 16 Weighted-average remaining lease term - finance leases (in years) 2 2 Weighted-average remaining lease term - operating leases (in years) 12 12 Weighted-average discount rate - finance leases 7.23 % 7.28 % Weighted-average discount rate - operating leases 10.32 % 9.44 % The weighted-average discount rate for the majority of the Company’s leases is based on the Company’s estimated incremental borrowing rate since the rates implicit in the leases were not determinable. The Company’s incremental borrowing rate is based on management’s estimate of the rate of interest the Company would have to pay to borrow on a fully collateralized basis over a similar term and amount equal to the lease payments. Future minimum lease payments under non-cancellable leases as of December 31, 2021 were as follows (in thousands): Year ending December 31, Operating Finance 2022 $ 4,068 $ 10 2023 3,247 3 2024 3,013 — 2025 3,091 — 2026 3,097 — Thereafter 23,935 — Total future minimum lease payments 40,451 13 Less imputed interest on commenced leases (17,832) — Total lease obligations $ 22,619 $ 13 Service Agreements The Company pays CTS a facility fee for the use of clean room/manufacturing, storage, and office space and for services in support of its manufacturing process including for routine sterilization of daily supplies, providing disposable supplies and microbial services, and office support. Pursuant to the CTS Agreement, the Company recorded expenses of $2,466, $1,739 and $2,148 for the years ended December 31, 2021, 2020 and 2019, respectively, in sales and marketing expenses. The CTS Agreement terminates December 31, 2023, subject to earlier termination by either party at any time for cause (subject to the non-terminating party’s right to cure, in certain circumstances), or without cause upon 6 months prior notice. In December 2011, the Company entered into a Master Services Agreement for Clinical Research and Related Services. The Company was required to pay $151 upon execution of this agreement and the remainder monthly based on activities associated with the execution of Axogen’s phase 3 pivotal clinical trial to support the BLA for Avance Nerve Graft. Payments made under this agreement were $1,100, $1,136 and $1,056 for the years ended December 31, 2021, 2020 and 2019, respectively. Distribution and Supply Agreements In August 2008, the Company entered into an exclusive distribution agreement with Cook Biotech to distribute the Axoguard Nerve Connector and Axoguard Nerve Protector products worldwide and the parties subsequently amended the agreement on February 26, 2018. Pursuant to the February 2018 amendment, the agreement expires on June 30, 2027. The Cook Biotech agreement establishes a formula for the transfer cost of the Axoguard products and requires certain minimum purchases by the Company, although, through mutual agreement, the parties have not established such minimums; and, to date, have not enforced such provision. Under the Cook Biotech agreement, the Company provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders. The agreement allows for termination provisions for both parties. The loss of the ability to sell the Axoguard products could have a material adverse effect on the Company's business until other replacement products would be available. In June 2017, the Company entered into the Nerve End Cap Supply Agreement (the "Supply Agreement") with Cook Biotech whereby Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessary licenses to their technologies for operation of the Supply Agreement. The Supply Agreement expires on August 27, 2027. Under the Supply Agreement the Company provides purchase orders to Cook Biotech and Cook Biotech fulfills the purchase orders. Axogen Processing Center Facility The Company is highly dependent on the continued availability of its processing facilities at CTS in Dayton, Ohio and could be harmed if the physical infrastructure of this facility is unavailable for any prolonged period of time. In addition, disruptions could lead to significant costs and reductions in revenue, as well as potential harm to the Company's business reputation and financial results. In the event of disruption, the Company believes it can find and make operational a new leased facility in less than six months, but the regulatory process for approval of facilities is time-consuming and unpredictable. The Company's ability to rebuild or find acceptable lease facilities could take a considerable amount of time and expense and could cause a significant disruption in service to its customers. Although the Company has business interruption insurance, which would cover certain costs, it may not cover all costs nor help to regain the Company's standing in the market. On July 31, 2018, the Company purchased the APC Facility in Vandalia, Ohio, located near the CTS processing facility where Avance Nerve Graft is currently processed. The APC Facility, when and if operational, will be the new processing facility for Avance Nerve Graft to provide continued capacity for growth and to support the transition of Avance Nerve Graft from a Human Cellular and Tissue-based Product pursuant to Section 361 of the Public Health Service Act to a biologic product. The APC Facility is comprised of a 107,000 square foot building on approximately 8.6 acres of land. The Company paid $731 for the land and this is recorded as land within property and equipment on the consolidated balance sheet. The Company paid $4,300 for the building and this is recorded in projects in process within property and equipment on the consolidated balance sheet. On July 9, 2019, the Company entered into a Standard Form of Agreement Between Owner and Design-Builder (the “Design-Build Agreement”) with CRB Builders, L.L.C., a Missouri limited liability company (“CRB”), pursuant to which CRB will renovate and retrofit the APC Facility. The Design-Build Agreement contains several design phase milestones that began in July 2019 and sets the date for Substantial Completion (as defined in the Design-Build Agreement) by late 2021, subject to adjustment in accordance with the terms of the Design-Build Agreement. The estimated cost pursuant to the Design-Build Agreement was $29,300. Additional costs associated with the renovation, validation and certification of the APC Facility are estimated to be $20,900, plus capitalized interest of $11,300. The Company temporarily deferred the construction as part of the cost containment initiatives implemented in the second quarter of 2020, and subsequently resumed construction in early January of 2021. For the year ended December 31, 2021, the Company has recorded $19,581 related to renovations and design and build in projects in progress. The Company has recorded $35,270 to date related to this project. In addition to these project costs, the Company has capitalized interest of $4,277 for the year ended December 31, 2021. To date, the Company has capitalized interest of $5,274 related to this project. These items are recorded as projects in process within property and equipment on the consolidated balance sheet. The Company anticipates spending $19,300, including projected capitalized interest of $6,100 in 2022 and an additional $1,700 in 2023. The Company anticipates that this building will be completed in early 2022, followed by a year-long process to validate and certify the facility by early 2023. The Company anticipates commencing tissue processing in the facility upon completion of the validation and certification process. The Company obtained certain economic development grants from state and local authorities totaling up to $2,685 including $1,250 of cash grants to offset costs to acquire and develop the APC Facility. The economic development grants are subject to certain job creation milestones by 2023 and related contingencies. The Company received $950 and $238 from these grants in the years ended December 31, 2021 and 2020, respectively. These grants have claw back clauses if the Company does not meet these job creation milestones by 2023. Fair Value of the Debt Derivative Liabilities The fair value of the Debt Derivative Liabilities is $5,562 as of December 31, 2021. The fair value of the Debt Derivative Liabilities was determined using a probability-weighted expected return model based upon the four potential settlement scenarios for the Oberland Facility which are described in Note 3 - Summary of Significant Accounting Policies – Derivative Instruments. The estimated settlement value of each scenario, which includes any required make-whole payment (see "Note 10 - Long-Term Debt, Net of Financing Fees"), is then discounted to present value using a discount rate that is derived based upon the initial terms of the Oberland Facility at issuance and corroborated utilizing a synthetic rating analysis. The calculated fair values under the four scenarios are then compared to the fair value of a plain vanilla note, with the difference reflecting the fair value of the Debt Derivative Liabilities. The Company estimated the make-whole payments required under each scenario according to the terms of the Oberland Facility to generate an internal rate of return equal to 11.5% through the scheduled maturity dates, less the total of all quarterly interest and royalty payments previously paid to Oberland Capital. The calculation utilized the XIRR function in Microsoft Excel as required by the Oberland Facility. If the debt is not prepaid but instead is held to its scheduled maturities, the Company’s estimate of the make-whole payment for the first tranche of the Oberland Facility is $68 on June 30, 2027, and the Company’s estimate of the make-whole payment for the second tranche of the Oberland Facility is zero on June 30, 2028. The Company has consistently applied this approach since the inception of the debt agreement on June 30, 2020. The Company has become aware that Oberland Capital may have an alternative interpretation of the calculation of the make-whole payments that the Company believes does not properly utilize the same methodology utilized by the XIRR function in Microsoft Excel as described in the Oberland Facility. The Company estimates the top end of the range of the make-whole payments if the debt is held to scheduled maturity under an alternative interpretation to be approximately $13,000 for the first tranche of the Oberland Facility on June 30, 2027, and approximately $5,000 for the second tranche of the Oberland Facility on June 30, 2028. Further, if the debt is prepaid prior to the scheduled maturity dates and subject to the alternative interpretation, the make-whole payment would be larger than the amounts herein. Other Commitments Certain executive officers of the Company are parties to employment contracts. Such contracts have severance payments for certain conditions including change of control. Legal Proceedings The Company is subject to various claims, lawsuits, and proceedings in the ordinary course of the Company's business, some of which have been dismissed by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Comp any's financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint in the United States District Court for the Middle District of Florida alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (“Individual Defendants”), and Axogen’s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the “Defendants”), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fla.). Plaintiff asserts that Defendants made false or misleading statements in connection with the Company’s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018. In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company’s pricing alienated customers and threatened the Company’s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company’s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company’s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company’s key operating metrics, such as the number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. Axogen was served on January 15, 2019. On February 4, 2019, the Court granted the parties’ stipulated motion which provided that Axogen is not required to file a response to the complaint until thirty days after Plaintiff files a consolidated amended complaint. On June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties’ obligations to file a case management report. On December 4, 2019, the parties presented oral arguments. On April 21, 2020, the Court dismissed the complaint without prejudice, finding the Plaintiff failed to state a claim upon which relief could be granted. The Plaintiff filed a Second Amended Class Action Complaint on June 22, 2020. Axogen filed a motion to dismiss on August 6, 2020. The Plaintiff filed an opposition on September 20, 2020. The Court held oral argument on February 25, 2021. On March 19, 2021, the Court dismissed the Second Amended Complaint with prejudice, finding again that the Plaintiff failed to state a claim upon which relief could be granted. On April 14, 2021, Plaintiff filed a notice of appeal. Plaintiff filed its opening brief on June 28, 2021. The Company filed its appellee brief on August 11, 2021. The Plaintiff filed a reply brief on September 14, 2021. The Eleventh Circuit has scheduled oral argument for March 8, 2022. The amount of loss, if any, cannot be reasonably estimated at this time. This matter is subject to various uncertainties and it is possible that it may be resolved unfavorably to the Company. However, while it is not possible to predict with certainty the outcome of the matter, the Company and the Individual Defendants dispute the allegations and intend to vigorously defend themselves. Bach v. Zaderej, et al., 27-cv-20-5997 (Hennepin Cnty., Minn.). On April 21, 2020, Plaintiff Michael Bach, derivatively on behalf of Axogen, filed a verified stockholder derivative complaint for breach of fiduciary duty, insider selling, corporate waste and unjust enrichment against Karen Zaderej, Gregory G. Freitag, Peter J. Mariani, Amy Wendell, Robert J. Rudelius, Mark Gold, Guido Neels, Jamie M. Grooms, Quentin S. Blackford, and Alan M. Levine (the “Individual Defendants”) and Nominal Defendant Axogen, Inc. (“Axogen”) (collectively, “Defendants”). The Bach Complaint was never served on Defendants and therefore no response was necessary. On November 14, 2021, Plaintiff Michael Bach filed a voluntary notice of dismissal without prejudice against all Defendants. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent EventOn January 27, 2022, the Company entered into an amendment to the April 21, 2015, as amended, lease with Ja-Cole, L.P. for 15,000 square feet of the Burleson Facility. The amendment revises the commencement date of the lease to mean May 1, 2022 and the termination date of the lease to be April 30, 2027. |
Schedule II - Valuation and Qua
Schedule II - Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2021 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
Schedule II - Valuation and Qualifying Accounts | Schedule II – Valuation and Qualifying Accounts AXOGEN, INC. SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS THREE YEARS ENDED DECEMBER 31, 2021, 2020 AND 2019 (in thousands) Balance at Beginning of Year Additions Deductions (Charge-offs) Balance at End of Year Allowance for doubtful accounts 2019 $ 1,117 $ 514 $ (539) $ 1,092 2020 $ 1,092 $ — $ (676) $ 416 2021 $ 416 $ — $ (140) $ 276 Valuation allowance for deferred tax assets 2019 $ 33,876 $ 6,056 $ — $ 39,932 2020 $ 39,932 $ 6,585 $ — $ 46,517 2021 $ 46,517 $ 6,734 $ — $ 53,251 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Cash and Cash Equivalents and Concentration | Cash and Cash Equivalents and Concentration The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying consolidated financial statements. The Company has not experienced any losses related to these balances; however, as of December 31, 2021, $32,238 of the cash and cash equivalents balance was in excess of Federal Deposit Insurance Corporation limits. As of December 31, 2021 and 2020, the Company had restricted cash balances of $6,251 and $6,842, respectively. The December 31, 2021 and 2020 balances both include $6,000, which represents collateral for an irrevocable standby letter of credit. Additionally, the December 31, 2021 balance includes an additional irrevocable standby letter of credit in the amount of $250 (See "Note 10 - Long-Term Debt, Net of Financing Fees"). |
Inventory | Inventory Inventory is comprised of unprocessed tissue, work-in-process, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Axotouch Two-Point Discriminator finished goods and supplies. Inventory is valued at the lower of cost (first-in, first-out) or net realizable value. Included within Inventory at December 31, 2020 is Avive Soft Tissue Membrane ("Avive"). On May 17, 2021, the Company announced that it would suspend market availability of Avive effective June 1, 2021 pending ongoing discussions with the FDA regarding the regulatory classification of Avive. The Company recorded a write-down of Avive inventory for an amount of $1,251 recorded in cost of goods sold in the consolidated statement of operations for the year ended December 31, 2021 related to this announcement. The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. To estimate the amount of inventory that will expire prior to being distributed, the Company reviews inventory quantities on hand, historical and projected distribution levels, and historical expiration trends. The Company’s calculation of the amount of inventory that will expire prior to distribution has two components: 1) a demand or consumption-based component that compares projected distribution to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being distributed. The Company’s model assumes that inventory will be distributed on a first-in, first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that significant portions of the Company’s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written down involves significant judgments and estimates. |
Investments | Investments The Company invests primarily in commercial paper and U.S. government securities and classifies all investments as available-for-sale. Investments are recorded at fair value. The Company elected the fair value option ("FVO") for all of its available-for-sale investments. The FVO election results in all changes in unrealized gains and losses being included in investment income in the consolidated statements of operations. |
Derivative Instruments | Derivative Instruments The Company reviews debt agreements for embedded features. If these features are not clearly and closely related to the debt host, they meet the definition of a derivative and require bifurcation from the host. All derivative instruments are recorded on the consolidated balance sheet at their respective fair values. The Company adjusts the carrying value of the derivative liability to fair value at each reporting date. The changes in the fair value of the derivatives are recorded in the consolidated statement of operations in the period in which they occur. The fair value of embedded derivatives are measured based on equity markets and interest rates, as well as an estimate of the Company's nonperformance risk adjustment. This estimate includes an option adjusted spread and an estimate of the Company's risk-free rate. |
Property and Equipment | Property and Equipment Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three When depreciable assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. |
Intangible Assets | Intangible Assets Intangible assets are recorded at cost and include patents and patent application costs, licenses, and trademarks. Intangible assets are amortized on a straight-line basis over their estimated useful lives of seventeen |
Revenue Recognition | Revenue Recognition The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection. Revenue is recognized when the Company has met its performance obligations pursuant to its customer contracts in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products and services to the Company’s customers. In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract. These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor’s cost. The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and therefore, the Company has determined it is appropriate to recognize revenue when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement. Determining the timing of revenue recognition for such contracts is subject to judgment, because an evaluation must be made regarding the distributor’s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company. Changes in these assessments could have an impact on the timing of revenue recognition from sales to distributors. A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of goods sold. The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing, and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers. The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company’s contracts vary; however, as a common business thirty |
Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk | Allowance for Doubtful Accounts Receivable and Concentration of Credit Risk The Company evaluates the collectability of accounts receivable to determine the appropriate allowance for doubtful accounts. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. An increase to the allowance for doubtful accounts results in a corresponding increase in general and administrative expense. The Company reviews accounts receivable and adjusts the allowance based on current circumstances and charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The Company’s history of write-offs has not been significant. The allowance for doubtful accounts balance was $276 and $416 at December 31, 2021 and 2020, respectively. Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the credit risk. The Company also controls credit risk through credit approvals and monitoring procedures. |
Leases | Leases The Company adopted Accounting Standards Update (“ASU”) No. 2016-2—Leases (Topic 842), effective January 1, 2019, using the modified retrospective approach. The Company determines whether or not a contract contains a lease at the inception date and determines the lease classification, recognition, and measurement at commencement date. The Company classifies a lease based on whether the arrangement is effectively a purchase of the underlying asset. Leases that transfer the control of the underlying asset are classified as finance leases and all others are classified as operating leases. Interest and amortization expense are recognized for operating leases on a straight-line basis. If a change to the lease term leads to a reassessment of the lease classification and remeasurement, assumptions such as the discount rate and variable rents based on a rate or index will be updated as of the remeasurement date. If an arrangement is modified, the Company will reassess whether the arrangement contains a lease. Any subsequent changes in lease payments are recognized when incurred, unless the change requires a remeasurement of the lease liability. The Company made an accounting policy election to not recognize right-of-use assets and lease obligations that arise from short-term leases, which are defined as leases with a lease term of 12 months or less at the lease commencement date. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company leases office space, medical lab and research space, a distribution center, a tissue processing center, and equipment. Certain of the Company's leases include options for the Company to extend the lease term. None of the options were reasonably certain of exercise, and therefore are not included in the measurement of lease obligations and right-of-use assets. Certain of the Company's lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. |
Net Loss Per Share | Net Loss Per Share Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested stock options, restricted stock units (“RSUs”), and performance stock units (“PSUs”). |
Research and Development Costs | Research and Development Costs Research and development costs are expensed as incurred and were $24,177, $17,846 and $17,514 for the years ended December 31, 2021, 2020 and 2019, respectively. |
Stock-Based Compensation | Stock-Based Compensation The Company measures all stock-based compensation awards, including stock options, RSUs, and PSUs at, or above, the fair market value of the Company's common stock on the date of grant. The Company estimates the fair value of each option award on the date of grant using a multiple-point Black-Scholes option-pricing model ("Black-Scholes") which uses a weighted average of historical volatility and peer company volatility. The Company’s determination of fair value is affected by the Company’s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the awards. The Company determines the expected life of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The expense has been reduced for forfeitures as they occur. The Company estimates the fair value of RSUs based upon the grant date closing market price of the Company’s common stock. With respect to PSUs, the number of shares that vest and are issued to the recipient is based upon the Company’s performance as measured against specified targets over the measurement period. The fair value of the PSUs is based on the Company’s closing stock price on the grant date and its estimate of achieving such performance targets. For further discussion and disclosures, see "Note 11 - Stock-Based Incentive Plans." The Company also has an employee stock purchase plan that is available to all eligible employees as defined by the plan document. Under the Axogen 2017 Employee Stock Purchase Plan ("2017 ESPP"), eligible employees may acquire shares of the Company’s common stock through payroll deductions at a discount to market price. The Company estimates the number of shares to be purchased under the 2017 ESPP at the beginning of each purchase period based upon the fair value of the stock at the beginning of the purchase period using the Black-Scholes model and records estimated compensation expense during the period. Expense is adjusted at the time of stock purchase. |
Use of Estimates | Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Management believes the critical accounting estimates relating to inventory, derivative instruments, and stock-based compensation affect the Company's more significant judgments and estimates used in the preparation of the Company’s consolidated financial statements. Actual results could differ materially from those estimates. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In November 2021, the Financial Accounting Standards Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832 ) , Disclosures by Business Entities about Government Assistance, which requires business entities to provide certain annual disclosures when they have received government assistance and use a grant or contribution accounting model by analogy to other accounting guidance (e.g., a grant model under International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance ). The disclosures should provide the nature of the transaction, including the significant terms and conditions of the transaction, the accounting policies used to account for the transaction, and the dollar amounts by line item on the financial statements that are affected by the transaction. The adoption of this ASU will be required beginning with the Company's Annual Report on Form 10-K for the year ending December 31, 2022, on either a prospective basis or retrospective basis. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. Recently Adopted Accounting Pronouncements Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Taxes, which was intended to simplify the accounting for income taxes by removing certain exceptions to the general rules found in Topic 740 - Income Taxes . The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. Effective January 1, 2021, the Company adopted ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs . The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Reconciliation of cash, cash equivalents and restricted cash | The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows: (in thousands) December 31, December 31, Cash and cash equivalents $ 32,756 $ 48,767 Restricted cash 6,251 6,842 Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows $ 39,007 $ 55,609 |
Schedule of balances of contract receivables and liabilities | The opening and closing balances of the Company’s contract receivables and liabilities are as follows: (in thousands) Net Receivables Contract Liabilities, Current Contract Liabilities, Long-Term Opening January 1, 2020 $ 16,944 $ 14 $ 15 Closing, December 31, 2020 17,618 14 3 Increase (decrease) 674 — (12) Opening January 1, 2021 $ 17,618 $ 14 $ 3 Closing, December 31, 2021 18,158 14 — Increase (decrease) 540 — (3) |
Inventory (Tables)
Inventory (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of inventory | Inventory consists of the following: (in thousands) December 31, December 31, Finished goods $ 11,011 $ 8,876 Work in process 813 751 Raw materials 4,869 2,902 Inventory $ 16,693 $ 12,529 |
Fair Value Measurement (Tables)
Fair Value Measurement (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Summary of significant inputs in liability valuation | The significant inputs that are included in the valuation of the Debt Derivative Liability - first tranche include: December 31, 2021 December 31, 2020 Input Remaining term (years) 5.5 6.5 Maturity date June 30, 2027 June 30, 2027 Coupon rate 9.50% 9.50% Revenue participation payments Maximum each year Maximum each year Discount rate 10.72% 1 8.70 % 1 Probability of mandatory prepayment before 2024 5.0% 1 5.0% 1 Estimated timing of mandatory prepayment event before 2024 December 31, 2023 1 December 31, 2023 1 Probability of mandatory prepayment 2024 or after 15.0% 1 15.0% 1 Estimated timing of mandatory prepayment event 2024 or after March 31, 2026 1 March 31, 2026 1 Probability of optional prepayment event 5.0% 1 5.0% 1 Estimated timing of optional prepayment event December 31, 2025 1 December 31, 2025 1 1 Represents a significant unobservable input. The significant inputs that are included in the valuation of the Debt Derivative Liability - second tranche include: December 31, 2021 Input Remaining term (years) 6.5 Maturity date June 30, 2028 Coupon rate 9.50% Revenue participation payments Maximum each year Discount rate 13.21 % (1) Probability of mandatory prepayment before 2024 5.0% (1) Estimated timing of mandatory prepayment event before 2024 December 31, 2023 (1) Probability of mandatory prepayment 2024 or after 15.0% (1) Estimated timing of mandatory prepayment event 2024 or after March 31, 2026 (1) Probability of optional prepayment event 5.0% (1) Estimated timing of optional prepayment event December 31, 2025 (1) 1 Represents a significant unobservable input. |
Summary of fair value financial assets measured on a recurring basis | The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020: (in thousands) Level 1 Level 2 Level 3 Total December 31, 2021 Assets: Money market funds $ 22,012 $ — $ — $ 22,012 U.S. government securities 12,081 — — 12,081 Commercial paper — 39,249 — 39,249 Total assets $ 34,093 $ 39,249 $ — $ 73,342 Liabilities: Debt derivative liabilities $ — $ — $ 5,562 $ 5,562 Total liabilities $ — $ — $ 5,562 $ 5,562 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market funds $ 23,044 $ — $ — $ 23,044 U.S. government securities 12,123 — — 12,123 Corporate bonds — 6,408 — 6,408 Commercial paper — 36,668 — 36,668 Total assets $ 35,167 $ 43,076 $ — $ 78,243 Liabilities: Debt derivative liability $ — $ — $ 2,497 $ 2,497 Total liabilities $ — $ — $ 2,497 $ 2,497 |
Schedule of fair value instruments classified Level 3 | The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows: (in thousands) Common Stock Derivative Option Liability Debt Derivative Liabilities Balance, December 31, 2019 $ — $ — Acquired 175 2,387 Change in fair value included in net loss 7 110 Settlement (182) — Balance, December 31, 2020 — 2,497 Acquired — 3,037 Change in fair value included in net loss — 28 Balance, December 31, 2021 $ — $ 5,562 |
Prepaid Expense and Other (Tabl
Prepaid Expense and Other (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of prepaid expense and other | Prepaid expenses and other consist of the following: (in thousands) December 31, 2021 December 31, 2020 Prepaid insurance $ — $ 2,596 Stock option receivable 3 2 Litigation receivable 23 23 Prepaid events 54 203 Prepaid marketing 620 587 Prepaid software license 215 220 Prepaid professional fees 207 251 Other prepaid items 739 414 Prepaid expenses and other $ 1,861 $ 4,296 |
Property and Equipment (Tables)
Property and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Schedule of property and equipment | Property and equipment, net consist of the following: (in thousands) December 31, December 31, Furniture and equipment $ 5,100 $ 2,334 Leasehold improvements 14,952 12,983 Processing equipment 3,984 2,634 Land 731 731 Projects in process 45,660 24,541 Property and equipment, at cost 70,427 43,223 Less: accumulated depreciation and amortization (7,546) (4,825) Property and equipment, net $ 62,881 $ 38,398 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of finite-lived intangible assets | ntangible assets consist of the following: December 31, 2021 December 31, 2020 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortizable intangible assets: Patents $ 2,469 $ (234) $ 2,235 $ 1,496 $ (139) $ 1,357 License agreements 1,101 (852) 249 1,093 (745) 348 Total amortizable intangible assets 3,570 (1,086) 2,484 2,589 (884) 1,705 Unamortized intangible assets: Trademarks 375 — 375 349 — 349 Total intangible assets $ 3,945 $ (1,086) $ 2,859 $ 2,938 $ (884) $ 2,054 |
Schedule of indefinite-lived intangible assets | ntangible assets consist of the following: December 31, 2021 December 31, 2020 (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortizable intangible assets: Patents $ 2,469 $ (234) $ 2,235 $ 1,496 $ (139) $ 1,357 License agreements 1,101 (852) 249 1,093 (745) 348 Total amortizable intangible assets 3,570 (1,086) 2,484 2,589 (884) 1,705 Unamortized intangible assets: Trademarks 375 — 375 349 — 349 Total intangible assets $ 3,945 $ (1,086) $ 2,859 $ 2,938 $ (884) $ 2,054 |
Schedule of future amortization | As of December 31, 2021, future amortization of patents and license agreements are as follows: Year Ending December 31, (in thousands) 2022 $ 233 2023 207 2024 130 2025 130 2026 129 Thereafter 1,655 Total $ 2,484 |
Accounts Payable and Accrued _2
Accounts Payable and Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |
Schedule of accounts payable and accrued expenses | Accounts payable and accrued expenses consist of the following: (in thousands) December 31, December 31, Accounts payable $ 5,923 $ 4,597 Accrued expenses 6,863 3,778 Accrued compensation 9,673 13,593 Accounts payable and accrued expenses $ 22,459 $ 21,968 |
Long-Term Debt, Net of Financ_2
Long-Term Debt, Net of Financing Fees (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of long-term debt instruments | Long-term debt, net of financing fees consists of the following: (in thousands) December 31, 2021 December 31, 2020 Oberland Facility - first tranche $ 35,000 $ 35,000 Oberland Facility - second tranche 15,000 — Less - unamortized debt discount and deferred financing fees (5,179) (2,973) Long-term debt, net of financing fees $ 44,821 $ 32,027 |
Stock-Based Incentive Plans (Ta
Stock-Based Incentive Plans (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Summary of Stock Option Activity | A summary of the stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding at December 31, 2019 3,420,181 $ 12.69 5.70 $ 26,074 Granted 663,098 $ 9.29 Forfeited (107,541) $ 19.71 Exercised (459,254) $ 5.36 Outstanding at December 31, 2020 3,516,484 $ 12.79 5.93 $ 25,718 Granted 656,398 $ 20.00 Forfeited (194,301) $ 17.02 Exercised (783,843) $ 5.89 Outstanding at December 31, 2021 3,194,738 $ 15.65 6.45 $ 2,236 Exercisable at December 31, 2021 1,865,381 $ 15.08 4.95 $ 1,932 |
Schedule of Weighted-Average Assumptions for Options Granted | The following weighted-average assumptions were used for stock options granted during the years ended December 31: Year Ended December 31, 2021 2020 2019 Expected term (in years) 5.88 5.88 5.76 Expected volatility 58.38 % 58.46 % 54.97 % Risk free rate 1.02 % 0.49 % 1.71 % Expected dividends — % — % — % |
Summary of Stock Unit Activity | A summary of the status of non-vested RSUs and PSUs as of December 31, 2021 and 2020 and the changes during the years then ended are as follows: Outstanding Restricted and Performance Stock Units Stock Units Weighted Weighted Average Remaining Vesting Life (Years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2019 1,113,697 $ 21.62 2.26 $ 19,800 Granted 1,008,869 $ 9.57 Released (247,333) $ 19.66 Forfeited (92,328) $ 18.64 Outstanding at December 31, 2020 1,782,905 $ 15.23 1.83 $ 31,825 Granted 898,264 $ 20.35 Released (253,881) $ 17.50 Forfeited (696,513) $ 13.00 Outstanding at December 31, 2021 1,730,775 $ 18.45 1.51 $ 19,633 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Differences Between the Carrying Amount of Assets and Liabilities for Financial Reporting Purposes and Their Respective Income Tax Basis | Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates. Deferred tax assets and deferred tax liabilities are as follows: (in thousands) December 31, December 31, Deferred tax assets: Net operating loss carryforwards $ 47,021 $ 42,317 Inventory write-down 653 397 Depreciation — Interest limitation 453 115 Allowance for doubtful accounts 70 106 Lease obligations 5,736 5,551 Stock-based compensation 3,985 3,218 Research and development credit 6 — Total deferred tax assets 57,924 51,704 Deferred tax liabilities: Depreciation (692) (1,145) Amortization (116) (34) Right-of-use assets (3,861) (4,004) Contract liabilities (4) (4) Total deferred tax liabilities (4,673) (5,187) Net deferred tax assets $ 53,251 $ 46,517 Valuation allowance $ (53,251) $ (46,517) |
Schedule of Effective Income Tax Rate Reconciliation | The Company’s effective income tax rate differs from the statutory federal income tax rate for the years ended December 31, 2021, 2020 and 2019 as follows: Year Ended December 31, 2021 2020 2019 Federal tax rate 21.0 % 21.0 % 21.0 % State taxes - net of Federal benefit 5.1 7.3 4.1 Permanent items and other deductions (1.4) (0.6) (4.3) Valuation allowance (24.7) (27.7) (20.8) Effective income tax rate — % — % — % |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Components of Total Lease Expense | The components of total lease expense for the years ended December 31, 2021, 2020 and 2019 were as follows: Year Ended December 31, (in thousands) 2021 2020 2019 Finance lease costs Amortization of right-of-use assets $ 22 $ 22 $ 22 Interest on lease obligations 2 3 4 Operating lease costs Operating lease costs 4,326 2,777 1,910 Short-term lease costs 10 116 41 Variable lease costs 744 18 17 Total lease expense $ 5,104 $ 2,936 $ 1,994 |
Schedule of Supplemental Balance Sheet Information Related to Leases | Supplemental balance sheet information related to leases as of December 31, 2021 and 2020 was as follows: (in thousands) December 31, December 31, Operating Leases Operating lease right-of-use assets $ 15,193 $ 15,614 Current maturities of long-term lease obligations $ 1,825 $ 846 Long-term lease obligations $ 20,794 $ 20,864 Finance Leases Finance lease right-of-use assets $ 42 $ 64 Current maturities of long-term lease obligations $ 9 $ 17 Long-term lease obligations $ 4 $ 13 |
Schedule of Other Information Related to Leases | Other information related to leases was as follows ($ in thousands): Year Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of operating lease obligations $ 1,537 $ 1,913 Right-of-use assets obtained in exchange for new finance lease obligations $ — $ 16 Weighted-average remaining lease term - finance leases (in years) 2 2 Weighted-average remaining lease term - operating leases (in years) 12 12 Weighted-average discount rate - finance leases 7.23 % 7.28 % Weighted-average discount rate - operating leases 10.32 % 9.44 % |
Schedule of Future Minimum Lease Payments, Operating Leases | Future minimum lease payments under non-cancellable leases as of December 31, 2021 were as follows (in thousands): Year ending December 31, Operating Finance 2022 $ 4,068 $ 10 2023 3,247 3 2024 3,013 — 2025 3,091 — 2026 3,097 — Thereafter 23,935 — Total future minimum lease payments 40,451 13 Less imputed interest on commenced leases (17,832) — Total lease obligations $ 22,619 $ 13 |
Schedule of Future Minimum Lease Payments, Finance Leases | Future minimum lease payments under non-cancellable leases as of December 31, 2021 were as follows (in thousands): Year ending December 31, Operating Finance 2022 $ 4,068 $ 10 2023 3,247 3 2024 3,013 — 2025 3,091 — 2026 3,097 — Thereafter 23,935 — Total future minimum lease payments 40,451 13 Less imputed interest on commenced leases (17,832) — Total lease obligations $ 22,619 $ 13 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands | 12 Months Ended | |||
Dec. 31, 2021USD ($)settlementScenario | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Mar. 31, 2021USD ($) | |
Cash and cash equivalents balance outside of FDIC limit | $ 32,238 | |||
Restricted cash | 6,251 | $ 6,842 | ||
Provision for inventory write-down | 3,314 | 2,242 | $ 1,887 | |
Accounts receivable, allowance for doubtful accounts | 276 | 416 | ||
Research and development | $ 24,177 | 17,846 | $ 17,514 | |
Debt derivative liabilities | Oberland Facility | ||||
Number of potential settlement scenarios | settlementScenario | 4 | |||
Debt derivative liabilities | Oberland Facility | Period One | ||||
Derivative liability, measurement input | 0.05 | |||
Debt derivative liabilities | Oberland Facility | Period Two | ||||
Derivative liability, measurement input | 0.15 | |||
Debt derivative liabilities | Oberland Facility | Period Three | Oberland Option | ||||
Derivative liability, measurement input | 0.05 | |||
Debt derivative liabilities | Oberland Facility | Period Four | ||||
Derivative liability, measurement input | 0.75 | |||
Minimum | ||||
Property and equipment, useful life (in years) | 3 years | |||
Intangible asset, useful life (in years) | 17 years | |||
Age of doubtful accounts | 30 days | |||
Maximum | ||||
Property and equipment, useful life (in years) | 7 years | |||
Intangible asset, useful life (in years) | 20 years | |||
Age of doubtful accounts | 60 days | |||
Avive Soft Tissue Membrane | ||||
Provision for inventory write-down | $ 1,251 | |||
Standby Letters of Credit | ||||
Collateral amount | $ 250 | |||
Standby Letters of Credit | Heights Union | ||||
Collateral amount | 250 | |||
Restricted Cash | ||||
Collateral amount | $ 6,000 | $ 6,000 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Reconciliation of Cash (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 32,756 | $ 48,767 | ||
Restricted cash | 6,251 | 6,842 | ||
Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows | $ 39,007 | $ 55,609 | $ 41,724 | $ 30,294 |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Contract Balances (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||
Net Receivables, Opening balance | $ 17,618 | $ 16,944 |
Net Receivables, Closing balance | 18,158 | 17,618 |
Increase/(decrease) | 540 | 674 |
Contract Liabilities, Current, Opening balance | 14 | 14 |
Contract Liabilities, Current, Closing balance | 14 | 14 |
Increase/(decrease) | 0 | 0 |
Contract Liabilities, Long-Term, Opening balance | 3 | 15 |
Contract Liabilities, Long-Term, Closing balance | 0 | 3 |
Increase/(decrease) | $ (3) | $ (12) |
Inventory (Details)
Inventory (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Finished goods | $ 11,011 | $ 8,876 |
Work in process | 813 | 751 |
Raw materials | 4,869 | 2,902 |
Inventory | $ 16,693 | $ 12,529 |
Inventory - Narrative (Details)
Inventory - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Inventory [Line Items] | |||
Inventory write-downs | $ 3,314 | $ 2,242 | $ 1,887 |
Provision for inventory write-down | 3,314 | $ 2,242 | $ 1,887 |
Avive Soft Tissue Membrane | |||
Inventory [Line Items] | |||
Inventory write-downs | 1,251 | ||
Provision for inventory write-down | $ 1,251 |
Fair Value Measurement - Narrat
Fair Value Measurement - Narrative (Details) $ in Thousands | Dec. 31, 2021USD ($)settlementScenario | Jun. 30, 2021USD ($) | Dec. 31, 2020USD ($) | Jun. 30, 2020USD ($) |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Long-term debt | $ 44,821 | $ 32,027 | ||
Oberland Facility | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Long-term debt | 45,325 | 32,623 | ||
Long-term debt, fair value | $ 52,605 | 36,855 | ||
Oberland Facility | Debt derivative liabilities | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Number of potential settlement scenarios | settlementScenario | 4 | |||
Oberland Facility | Debt derivative liabilities | Period One | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Derivative liability, measurement input | 0.05 | |||
Oberland Facility | Debt derivative liabilities | Period Two | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Derivative liability, measurement input | 0.15 | |||
Oberland Facility | Debt derivative liabilities | Period Three | Oberland Option | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Derivative liability, measurement input | 0.05 | |||
Oberland Facility | Debt derivative liabilities | Period Four | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Derivative liability, measurement input | 0.75 | |||
Tranche One | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Principal balance | $ 35,000 | 35,000 | $ 35,000 | |
Tranche Two | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Principal balance | $ 15,000 | $ 15,000 | $ 0 |
Fair Value Measurement - Signif
Fair Value Measurement - Significant Inputs Included in the Valuation of the Debt Derivative Liability (Details) - Debt derivative liabilities | Dec. 31, 2021 | Dec. 31, 2020 |
Tranche One | Remaining term (years) | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 5.5 | 6.5 |
Tranche One | Coupon rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.0950 | 0.0950 |
Tranche One | Discount rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.1072 | 0.0870 |
Tranche One | Mandatory Prepayment Rate | Probability of mandatory prepayment before 2024 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.050 | 0.050 |
Tranche One | Mandatory Prepayment Rate | Probability of mandatory prepayment 2024 or after | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.150 | 0.150 |
Tranche One | Mandatory Prepayment Rate | Probability of optional prepayment event | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.050 | 0.050 |
Tranche Two | Remaining term (years) | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 6.5 | |
Tranche Two | Coupon rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.0950 | |
Tranche Two | Discount rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.1321 | |
Tranche Two | Mandatory Prepayment Rate | Probability of mandatory prepayment before 2024 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.050 | |
Tranche Two | Mandatory Prepayment Rate | Probability of mandatory prepayment 2024 or after | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.150 | |
Tranche Two | Mandatory Prepayment Rate | Probability of optional prepayment event | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative liability, measurement input | 0.050 |
Fair Value Measurement - Schedu
Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 |
Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt derivative liabilities | $ 5,562 | $ 2,387 | |
Recurring | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 73,342 | $ 78,243 | |
Total liabilities | 5,562 | 2,497 | |
Recurring | Money market funds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 22,012 | 23,044 | |
Recurring | U.S. government securities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 12,081 | 12,123 | |
Recurring | Corporate bonds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 6,408 | ||
Recurring | Commercial paper | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 39,249 | 36,668 | |
Recurring | Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt derivative liabilities | 5,562 | 2,497 | |
Recurring | Level 1 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 34,093 | 35,167 | |
Total liabilities | 0 | 0 | |
Recurring | Level 1 | Money market funds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 22,012 | 23,044 | |
Recurring | Level 1 | U.S. government securities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 12,081 | 12,123 | |
Recurring | Level 1 | Corporate bonds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | ||
Recurring | Level 1 | Commercial paper | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | 0 | |
Recurring | Level 1 | Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt derivative liabilities | 0 | 0 | |
Recurring | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 39,249 | 43,076 | |
Total liabilities | 0 | 0 | |
Recurring | Level 2 | Money market funds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | 0 | |
Recurring | Level 2 | U.S. government securities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | 0 | |
Recurring | Level 2 | Corporate bonds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 6,408 | ||
Recurring | Level 2 | Commercial paper | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 39,249 | 36,668 | |
Recurring | Level 2 | Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt derivative liabilities | 0 | 0 | |
Recurring | Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | 0 | |
Total liabilities | 5,562 | 2,497 | |
Recurring | Level 3 | Money market funds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | 0 | |
Recurring | Level 3 | U.S. government securities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | 0 | |
Recurring | Level 3 | Corporate bonds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | ||
Recurring | Level 3 | Commercial paper | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total assets | 0 | 0 | |
Recurring | Level 3 | Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt derivative liabilities | $ 5,562 | $ 2,497 |
Fair Value Measurement - Fair V
Fair Value Measurement - Fair Value of Instruments Classified as Level 3 (Details) - Level 3 - Recurring - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Common Stock Derivative Option Liability | ||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Beginning balance | $ 0 | $ 0 |
Acquired | 0 | 175 |
Change in fair value included in net loss | 0 | 7 |
Settlement | (182) | |
Ending Balance | 0 | 0 |
Debt derivative liabilities | ||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Beginning balance | 2,497 | 0 |
Acquired | 3,037 | 2,387 |
Change in fair value included in net loss | 28 | 110 |
Settlement | 0 | |
Ending Balance | $ 5,562 | $ 2,497 |
Prepaid Expenses and Other - Sc
Prepaid Expenses and Other - Schedule of Prepaid Expense and Other (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Prepaid insurance | $ 0 | $ 2,596 |
Stock option receivable | 3 | 2 |
Litigation receivable | 23 | 23 |
Prepaid events | 54 | 203 |
Prepaid marketing | 620 | 587 |
Prepaid software license | 215 | 220 |
Prepaid professional fees | 207 | 251 |
Other prepaid items | 739 | 414 |
Prepaid expenses and other | $ 1,861 | $ 4,296 |
Prepaid Expense and Other - Nar
Prepaid Expense and Other - Narrative (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Prepaid insurance | $ 0 | $ 2,596 |
Property and Equipment (Details
Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Property and equipment | ||
Property and equipment, at cost | $ 70,427 | $ 43,223 |
Less: accumulated depreciation and amortization | (7,546) | (4,825) |
Property and equipment, net | 62,881 | 38,398 |
Furniture and equipment | ||
Property and equipment | ||
Property and equipment, at cost | 5,100 | 2,334 |
Leasehold improvements | ||
Property and equipment | ||
Property and equipment, at cost | 14,952 | 12,983 |
Processing equipment | ||
Property and equipment | ||
Property and equipment, at cost | 3,984 | 2,634 |
Land | ||
Property and equipment | ||
Property and equipment, at cost | 731 | 731 |
Projects in process | ||
Property and equipment | ||
Property and equipment, at cost | $ 45,660 | $ 24,541 |
Property and Equipment - Narrat
Property and Equipment - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Property, Plant and Equipment [Abstract] | |||
Depreciation and amortization | $ 2,721 | $ 1,507 | $ 933 |
Intangible Assets - Components
Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Amortizable intangible assets: | ||
Gross Carrying Amount | $ 3,570 | $ 2,589 |
Accumulated Amortization | (1,086) | (884) |
Net Carrying Amount | 2,484 | 1,705 |
Unamortized intangible assets: | ||
Intangible assets, gross | 3,945 | 2,938 |
Intangible assets, net | 2,859 | 2,054 |
Trademarks | ||
Unamortized intangible assets: | ||
Carrying Amount | 375 | 349 |
Patents | ||
Amortizable intangible assets: | ||
Gross Carrying Amount | 2,469 | 1,496 |
Accumulated Amortization | (234) | (139) |
Net Carrying Amount | 2,235 | 1,357 |
License agreements | ||
Amortizable intangible assets: | ||
Gross Carrying Amount | 1,101 | 1,093 |
Accumulated Amortization | (852) | (745) |
Net Carrying Amount | $ 249 | $ 348 |
Intangible Assets - Narrative (
Intangible Assets - Narrative (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Jan. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Intangible assets | ||||
Amortization of intangible assets | $ 202 | $ 153 | $ 123 | |
Impairment of intangible assets | $ 104 | |||
Sales and Marketing Expense | ||||
Intangible assets | ||||
Royalty fees included in sales and marketing expense | $ 2,715 | $ 2,289 | $ 2,119 | |
License agreements | ||||
Intangible assets | ||||
Notice period for termination of license agreements | 60 days | |||
Minimum royalty of agreements | $ 13 | |||
Milestone fee upon receiving a Phase II Small Business Innovation Research | 15 | |||
Milestone fee upon FDA approval | 2 | |||
Milestone fee upon first commercial use of certain licensed technology | 25 | |||
Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products | $ 10 | |||
Minimum | License agreements | ||||
Intangible assets | ||||
Amortization period of intangible assets | 17 years | |||
Royalty fees range under the license agreements | 1.00% | |||
Maximum | License agreements | ||||
Intangible assets | ||||
Amortization period of intangible assets | 20 years | |||
Royalty fees range under the license agreements | 3.00% | |||
Royalty stack cap for royalties paid to more than one licensor for sales of the same product | 3.75% | |||
Maximum | Patents | ||||
Intangible assets | ||||
Amortization period of intangible assets | 20 years |
Intangible Assets - Future Amor
Intangible Assets - Future Amortization of Patents and License Agreements (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Intangible assets | ||
Net Carrying Amount | $ 2,484 | $ 1,705 |
Patents And License Agreements | ||
Intangible assets | ||
2022 | 233 | |
2023 | 207 | |
2024 | 130 | |
2025 | 130 | |
2026 | 129 | |
Thereafter | 1,655 | |
Net Carrying Amount | $ 2,484 |
Accounts Payable and Accrued _3
Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Accounts Payable and Accrued Liabilities, Current [Abstract] | ||
Accounts payable | $ 5,923 | $ 4,597 |
Accrued expenses | 6,863 | 3,778 |
Accrued compensation | 9,673 | 13,593 |
Accounts payable and accrued expenses | $ 22,459 | $ 21,968 |
Long-Term Debt, Net of Financ_3
Long-Term Debt, Net of Financing Fees - Schedule of Carrying Values of Outstanding Debt (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | Jun. 30, 2020 |
Note Payable | ||||
Less - unamortized debt discount and deferred financing fees | $ (5,179) | $ (2,973) | ||
Long-term debt, net of financing fees | 44,821 | 32,027 | ||
Tranche One | ||||
Note Payable | ||||
Long-term debt, gross | 35,000 | 35,000 | $ 35,000 | |
Tranche Two | ||||
Note Payable | ||||
Long-term debt, gross | $ 15,000 | $ 15,000 | $ 0 |
Long-Term Debt, Net of Financ_4
Long-Term Debt, Net of Financing Fees - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 10, 2020 | Jun. 30, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jun. 30, 2021 | Mar. 31, 2021 | Apr. 23, 2020 |
Debt Instrument [Line Items] | ||||||||
Interest expense | $ 1,356 | $ 1,054 | $ 40 | |||||
Long-term debt | 44,821 | 32,027 | ||||||
Standby Letters of Credit | ||||||||
Debt Instrument [Line Items] | ||||||||
Collateral amount | $ 250 | |||||||
Restricted Cash | ||||||||
Debt Instrument [Line Items] | ||||||||
Collateral amount | 6,000 | 6,000 | ||||||
Debt derivative liabilities | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt derivative liabilities | $ 2,387 | 5,562 | ||||||
Oberland Option | ||||||||
Debt Instrument [Line Items] | ||||||||
Exercise price of warrants (in USD per share) | $ 14.13 | |||||||
Debt derivative liabilities | $ 175 | |||||||
Oberland Option | TPC Investments II LP | ||||||||
Debt Instrument [Line Items] | ||||||||
Number of shares called by warrants (in shares) | 247,699 | |||||||
Oberland Facility | ||||||||
Debt Instrument [Line Items] | ||||||||
Term of debt | 7 years | |||||||
Financing costs | $ 642 | |||||||
Financing costs paid | $ 642 | |||||||
Period for which quarterly interest payments are required | 7 years | |||||||
Interest rate | 7.50% | |||||||
Interest rate at period end | 9.50% | |||||||
Threshold revenue achievement for payment of additional quarterly royalty | $ 70,000 | |||||||
Additional payment percentage | 1.00% | |||||||
Interest expense | $ 646 | |||||||
Interest paid | 4,103 | 1,709 | ||||||
Interest costs capitalized | 4,277 | 997 | ||||||
Accumulated capitalized interest costs | 5,274 | |||||||
Make-whole payment, minimum required internal rate of return | 11.50% | |||||||
Interest rate increase in the event of default | 4.00% | |||||||
Liquidity covenant multiplier | 1.1 | |||||||
Long-term debt | $ 45,325 | 32,623 | ||||||
Oberland Facility | Each of Third And Fourth Quarter of 2020 | ||||||||
Debt Instrument [Line Items] | ||||||||
Revenue target | $ 8,750 | |||||||
Oberland Facility | Each Of The First And Second Quarter of 2021 | ||||||||
Debt Instrument [Line Items] | ||||||||
Revenue target | 17,500 | |||||||
Oberland Facility | Each Quarter Thereafter | ||||||||
Debt Instrument [Line Items] | ||||||||
Revenue target | 20,000 | |||||||
Oberland Facility | Oberland Option | ||||||||
Debt Instrument [Line Items] | ||||||||
Value of warrants outstanding | $ 3,500 | |||||||
Moving average of closing stock | 45 days | |||||||
Gross proceeds from warrant exercises | $ 3,500 | |||||||
Oberland Facility | LIBOR | ||||||||
Debt Instrument [Line Items] | ||||||||
Additional interest floor rate | 2.00% | |||||||
Tranche One | ||||||||
Debt Instrument [Line Items] | ||||||||
Principal balance | $ 35,000 | $ 35,000 | 35,000 | |||||
Tranche One | Debt derivative liabilities | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt derivative liabilities | 1,076 | |||||||
Tranche Two | ||||||||
Debt Instrument [Line Items] | ||||||||
Principal balance | $ 15,000 | $ 0 | 15,000 | |||||
Tranche Two | Debt derivative liabilities | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt derivative liabilities | $ 1,961 | |||||||
Paycheck Protection Program Loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Long-term debt | $ 7,820 |
Stock-Based Incentive Plans - O
Stock-Based Incentive Plans - Overview of Equity Incentive Plans Narrative (Details) $ in Thousands | May 10, 2021shares | Dec. 31, 2021USD ($)planshares | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | May 10, 2021shares | Aug. 14, 2019shares |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Share-based incentive plans | plan | 2 | |||||
Share-based compensation expense | $ | $ 10,919 | $ 8,470 | $ 10,304 | |||
Unrecognized compensation costs related to non-vested stock options and restricted stock awards | $ | $ 19,502 | |||||
Stock options | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Weighted average period of recognition of unrecognized compensation expense | 2 years 1 month 2 days | |||||
RSUs | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Weighted average period of recognition of unrecognized compensation expense | 2 years 14 days | |||||
2019 Plan | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Additional shares authorized for future issuance (in shares) | 2,500,000 | 5,500,000 | ||||
Shares authorized for issuance (in shares) | 5,885,482 | 3,630,823 | 5,885,482 | |||
Unallocated shares available for issuance (in shares) | 385,482 |
Stock-Based Incentive Plans - S
Stock-Based Incentive Plans - Stock Options Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Proceeds from exercise of stock options and ESPP stock purchases | $ 5,467 | $ 3,300 | $ 4,002 |
Intrinsic value of options exercised | $ 14,167 | $ 5,595 | $ 9,553 |
Prior Axogen Plan | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period (in years) | 7 years | ||
Prior Axogen Plan | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period (in years) | 10 years | ||
Stock options | Prior Axogen Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period (in years) | 4 years | ||
Stock options | Prior Axogen Plan | One Year After Grant Date | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting percentage | 25.00% | ||
Vesting period (in years) | 1 year | ||
Stock options | Prior Axogen Plan | Tranche Two | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting percentage | 12.50% | ||
Vesting period (in years) | 3 years | ||
Stock options | 2017 ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period (in years) | 4 years | ||
Stock options | 2017 ESPP | Tranche Two | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting percentage | 12.50% | ||
Vesting period (in years) | 2 years | ||
Stock options | 2017 ESPP | Tranche One | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting percentage | 50.00% | ||
Vesting period (in years) | 2 years | ||
Directors And Officers Stock Options | Per Quarter, Over One Year | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting percentage | 25.00% | ||
Vesting period (in years) | 1 year | ||
Directors And Officers Stock Options | 2017 ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period (in years) | 3 years |
Stock-Based Incentive Plans -_2
Stock-Based Incentive Plans - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Options | |||
Outstanding at the beginning of the period (in shares) | 3,516,484 | 3,420,181 | |
Granted (in shares) | 656,398 | 663,098 | |
Forfeited (in shares) | (194,301) | (107,541) | |
Exercised (in shares) | (783,843) | (459,254) | |
Outstanding at the end of the period (in shares) | 3,194,738 | 3,516,484 | 3,420,181 |
Exercisable (in shares) | 1,865,381 | ||
Weighted Average Exercise Price | |||
Outstanding at the beginning of the period (in USD per share) | $ 12.79 | $ 12.69 | |
Granted (in USD per share) | 20 | 9.29 | |
Forfeited (in USD per share) | 17.02 | 19.71 | |
Exercised (in USD per share) | 5.89 | 5.36 | |
Outstanding at the end of the period (in USD per share) | 15.65 | $ 12.79 | $ 12.69 |
Exercisable (in USD per share) | $ 15.08 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] | |||
Weighted average remaining contractual term, outstanding (in years) | 6 years 5 months 12 days | 5 years 11 months 4 days | 5 years 8 months 12 days |
Weighted average remaining contractual term, exercisable (in years) | 4 years 11 months 12 days | ||
Aggregate intrinsic value, outstanding | $ 2,236 | $ 25,718 | $ 26,074 |
Aggregate intrinsic value, exercisable | $ 1,932 |
Stock-Based Incentive Plans -_3
Stock-Based Incentive Plans - Summary of Weighted-Average Assumptions Used (Details) - Stock options | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (in years) | 5 years 10 months 17 days | 5 years 10 months 17 days | 5 years 9 months 3 days |
Expected volatility | 58.38% | 58.46% | 54.97% |
Risk free rate | 1.02% | 0.49% | 1.71% |
Expected dividends | 0.00% | 0.00% | 0.00% |
Stock-Based Incentive Plans - R
Stock-Based Incentive Plans - Restricted and Performance Stock Units Narrative (Details) - USD ($) $ in Thousands | Mar. 16, 2021 | Dec. 17, 2019 | Dec. 27, 2018 | Dec. 18, 2017 | Jul. 31, 2020 | Jun. 30, 2020 | Dec. 31, 2021 | Sep. 30, 2021 | Dec. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jul. 17, 2020 | Mar. 16, 2020 |
RSUs | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Vesting period (in years) | 4 years | ||||||||||||||
Total fair value of restricted stock vested | $ 4,481 | $ 3,811 | $ 1,467 | ||||||||||||
RSUs | Directors And Certain Executive Officers | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Vesting period (in years) | 3 years | ||||||||||||||
RSUs | Directors And Certain Executive Officers | Tranche One | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Vesting period (in years) | 1 year | ||||||||||||||
PSUs | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Vesting period (in years) | 3 years | ||||||||||||||
Unrecognized compensation expense | $ 484 | $ 484 | |||||||||||||
PSU - BLA Milestones | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Shares authorized for issuance (in shares) | 378,863 | ||||||||||||||
Shares available (in shares) | 298,587 | 298,587 | |||||||||||||
PSU - BLA Milestones | Tranche One | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Vesting percentage | 50.00% | 50.00% | |||||||||||||
PSU - BLA Milestones | Tranche Two | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Vesting period (in years) | 1 year | 1 year | |||||||||||||
Vesting percentage | 50.00% | 50.00% | |||||||||||||
2017 PSUs | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Shares authorized for issuance (in shares) | 114,700 | ||||||||||||||
Achievement of award issued (as a percent) | 72.30% | ||||||||||||||
Percentage of stock compensation | 27.70% | ||||||||||||||
Value of grants reversed | $ 536 | ||||||||||||||
2018 PSUs | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Shares authorized for issuance (in shares) | 130,400 | ||||||||||||||
Value of grants reversed | $ 1,161 | ||||||||||||||
2020 PSUs | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Shares authorized for issuance (in shares) | 144,300 | 357,000 | |||||||||||||
Achievement of award issued (as a percent) | 110.00% | 50.00% | |||||||||||||
Value of grants reversed | $ 340 | $ 804 | |||||||||||||
2021 PSUs | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Shares authorized for issuance (in shares) | 332,200 | ||||||||||||||
Value of grants reversed | $ 1,831 | ||||||||||||||
2021 PSUs | Minimum | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Performance stock unit, payout opportunity | 0.00% | ||||||||||||||
2021 PSUs | Maximum | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||
Performance stock unit, payout opportunity | 200.00% |
Stock-Based Incentive Plans -_4
Stock-Based Incentive Plans - Summary of Restricted and Performance Stock Units (Details) - Restricted and Performance Stock Units - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Restricted and Performance Stock Units | |||
Outstanding at the beginning of the period (in shares) | 1,782,905 | 1,113,697 | |
Granted (in shares) | 898,264 | 1,008,869 | |
Released (in shares) | (253,881) | (247,333) | |
Forfeited (in shares) | (696,513) | (92,328) | |
Outstanding at the end of the period (in shares) | 1,730,775 | 1,782,905 | 1,113,697 |
Weighted Average Exercise Price | |||
Outstanding at the beginning of the period (in USD per share) | $ 15.23 | $ 21.62 | |
Granted (in USD per share) | 20.35 | 9.57 | |
Released (in USD per share) | 17.50 | 19.66 | |
Forfeited (in USD per share) | 13 | 18.64 | |
Outstanding at the end of the period (in USD per share) | $ 18.45 | $ 15.23 | $ 21.62 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] | |||
Weighted Average Remaining Vesting Life (Years) | 1 year 6 months 3 days | 1 year 9 months 29 days | 2 years 3 months 3 days |
Aggregate intrinsic value, outstanding | $ 19,633 | $ 31,825 | $ 19,800 |
Stock-Based Incentive Plans - E
Stock-Based Incentive Plans - Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation expense | $ 10,919 | $ 8,470 | $ 10,304 |
2017 ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Discount from market value on common stock | 15.00% | ||
Offering period | 6 months | ||
Maximum amount available to participants per year | $ 25 | ||
Shares authorized for issuance (in shares) | 600,000 | ||
Shares available (in shares) | 223,678 | ||
2017 ESPP | Employee Stock | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation expense | $ 401 | $ 493 | $ 744 |
Income Taxes - Temporary Differ
Income Taxes - Temporary Differences (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred tax assets: | ||
Net operating loss carryforwards | $ 47,021 | $ 42,317 |
Inventory write-down | 653 | 397 |
Depreciation | 0 | |
Interest limitation | 453 | 115 |
Allowance for doubtful accounts | 70 | 106 |
Lease obligations | 5,736 | 5,551 |
Stock-based compensation | 3,985 | 3,218 |
Research and development credit | 6 | 0 |
Total deferred tax assets | 57,924 | 51,704 |
Deferred tax liabilities: | ||
Depreciation | (692) | (1,145) |
Amortization | (116) | (34) |
Right-of-use assets | (3,861) | (4,004) |
Contract liabilities | (4) | (4) |
Total deferred tax liabilities | (4,673) | (5,187) |
Net deferred tax assets | 53,251 | 46,517 |
Valuation allowance | $ (53,251) | $ (46,517) |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||
Change in valuation allowance | $ 6,734,000 | $ 6,585,000 | |
Operating loss carryforwards | 47,021,000 | ||
Income tax expense (benefit) | $ 0 | $ 0 | $ 0 |
Income Taxes - Effective Income
Income Taxes - Effective Income Tax Rate Reconciliation (Details) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | |||
Federal tax benefit rate | 21.00% | 21.00% | 21.00% |
State Taxes - Net of Federal Benefit | 5.10% | 7.30% | 4.10% |
Permanent items and other deductions | (1.40%) | (0.60%) | (4.30%) |
Valuation allowance | (24.70%) | (27.70%) | (20.80%) |
Effective income tax rate | 0.00% | 0.00% | 0.00% |
Employee Benefit Plan (Details)
Employee Benefit Plan (Details) - AxoGen 401K Plan $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | |
Defined Benefit Plan | |||
Age limit for eligibility to participate in the plan | 18 | ||
Employer contributions | $ 1,346 | $ 1,141 | $ 988 |
Employer's contribution, first tranche | |||
Defined Benefit Plan | |||
Matching contributions | 3.00% | ||
Employee contribution matched, percent | 3.00% | ||
Employer's contribution, second tranche | |||
Defined Benefit Plan | |||
Matching contributions | 1.00% | ||
Employee contribution matched, percent | 2.00% |
Commitments and Contingencies -
Commitments and Contingencies - Leases Narrative (Details) ft² in Thousands, $ in Thousands | Jul. 12, 2021 | Aug. 28, 2020USD ($) | Aug. 06, 2015 | Jan. 27, 2022ft² | Dec. 31, 2021USD ($)ft² | Jul. 13, 2021USD ($) | Dec. 31, 2020USD ($) | Oct. 01, 2020ft² | Feb. 06, 2007ft² |
Commitments and Contingencies | |||||||||
Operating lease right-of-use assets | $ 15,193 | $ 15,614 | |||||||
Operating lease liability | $ 22,619 | ||||||||
CTS Agreement | |||||||||
Commitments and Contingencies | |||||||||
Service agreement term | 5 years | ||||||||
Corporate Headquarters Facility | |||||||||
Commitments and Contingencies | |||||||||
Area of lease property | ft² | 19,000 | ||||||||
Operating lease right-of-use assets | $ 1,335 | ||||||||
Operating lease liability | $ 1,370 | ||||||||
Heights Union | |||||||||
Commitments and Contingencies | |||||||||
Area of lease property | ft² | 75,000 | ||||||||
Operating lease right-of-use assets | $ 13,323 | ||||||||
Operating lease liability | 18,573 | ||||||||
Operating lease, lessor allowance | $ 5,250 | ||||||||
Number of months of free rent pursuant to lease amendment | 1 month 15 days | ||||||||
Operating lease, incremental borrowing rate | 10.60% | ||||||||
Burleson Facility | |||||||||
Commitments and Contingencies | |||||||||
Area of lease property | ft² | 17,500 | ||||||||
Burleson Facility | Subsequent Event | |||||||||
Commitments and Contingencies | |||||||||
Area of lease property | ft² | 15,000 |
Commitments and Contingencies_2
Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Lease, Cost [Abstract] | |||
Finance lease costs, Amortization of right-of-use assets | $ 22 | $ 22 | $ 22 |
Finance lease costs, Interest on lease liabilities | 2 | 3 | 4 |
Operating lease costs | 4,326 | 2,777 | 1,910 |
Short-term lease costs | 10 | 116 | 41 |
Variable lease costs | 744 | 18 | 17 |
Total lease expense | $ 5,104 | $ 2,936 | $ 1,994 |
Commitments and Contingencies_3
Commitments and Contingencies - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Operating Leases | ||
Operating lease right-of-use assets | $ 15,193 | $ 15,614 |
Current maturities of long-term obligations | $ 1,825 | $ 846 |
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Current maturities of long-term lease obligations | Current maturities of long-term lease obligations |
Long term obligations | $ 20,794 | $ 20,864 |
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Long-term lease obligations | Long-term lease obligations |
Finance Leases | ||
Finance lease right-of-use assets | $ 42 | $ 64 |
Current maturities of long-term obligations | $ 9 | $ 17 |
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Current maturities of long-term lease obligations | Current maturities of long-term lease obligations |
Long term obligations | $ 4 | $ 13 |
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Long-term lease obligations | Long-term lease obligations |
Commitments and Contingencies_4
Commitments and Contingencies - Other Information Related to Leases (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Cash paid for amounts included in the measurement of operating lease obligations | $ 1,537 | $ 1,913 |
Right-of-use assets obtained in exchange for new finance lease obligations | $ 0 | $ 16 |
Weighted-average remaining lease term - finance leases (in years) | 2 years | 2 years |
Weighted-average remaining lease term - operating leases (in years) | 12 years | 12 years |
Weighted-average discount rate - finance leases | 7.23% | 7.28% |
Weighted-average discount rate - operating leases | 10.32% | 9.44% |
Commitments and Contingencies_5
Commitments and Contingencies - Maturities of Lease Payments (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Operating Leases | |
2022 | $ 4,068 |
2023 | 3,247 |
2024 | 3,013 |
2025 | 3,091 |
2026 | 3,097 |
Thereafter | 23,935 |
Total future minimum lease payments | 40,451 |
Less imputed interest on commenced leases | (17,832) |
Total lease obligations | 22,619 |
Finance Leases | |
2022 | 10 |
2023 | 3 |
2024 | 0 |
2025 | 0 |
2026 | 0 |
Thereafter | 0 |
Total future minimum lease payments | 13 |
Less imputed interest on commenced leases | 0 |
Total lease obligations | $ 13 |
Commitments and Contingencies_6
Commitments and Contingencies - Service Agreements Narrative (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Dec. 31, 2011 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
CTS Agreement | ||||
Service Agreements | ||||
License fee amount | $ 2,466 | $ 1,739 | $ 2,148 | |
Notice period for termination of agreement | 6 months | |||
Master Services Agreement For Clinical Research and Related Services | ||||
Service Agreements | ||||
Service agreement amount paid upon execution of agreement | $ 151 | |||
Payment for service fees | $ 1,100 | $ 1,136 | $ 1,056 |
Commitments and Contingencies_7
Commitments and Contingencies - Axogen Processing Center Facility Narrative (Details) ft² in Thousands, $ in Thousands | Jul. 09, 2019USD ($) | Jul. 31, 2018USD ($)ft²a | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2021USD ($) |
Design build agreement | |||||
Concentrations | |||||
Estimated cost relating to design build agreement | $ 29,300 | ||||
Additional costs associated with design build agreement | 20,900 | ||||
Interest costs capitalized | $ 11,300 | ||||
Design build agreement | Projects in process | |||||
Concentrations | |||||
Expenses related to improvements in current year | $ 19,581 | $ 35,270 | |||
Interest costs capitalized | 4,277 | ||||
Accumulated capitalized interest costs | 5,274 | 5,274 | |||
Anticipated costs associated with design build agreement, in 2022 | 19,300 | 19,300 | |||
Projected capitalized interest, in 2022 | 6,100 | ||||
Anticipated costs associated with design build agreement, in 2023 | 1,700 | 1,700 | |||
APC Facility | |||||
Concentrations | |||||
Size of building space | ft² | 107 | ||||
Area of land where building resides | a | 8.6 | ||||
Payments to acquire Land | $ 731 | ||||
Payments to acquire Building | $ 4,300 | ||||
APC Facility | Design build agreement | |||||
Concentrations | |||||
Receivable economic development grants from state and local authorities (up to) | 2,685 | 2,685 | |||
Cash grants receivable (up to) | 1,250 | $ 1,250 | |||
Proceeds from grantors | $ 950 | $ 238 |
Commitments and Contingencies_8
Commitments and Contingencies - Fair Value of Debt Derivative Liabilities (Details) | Dec. 31, 2021USD ($)settlementScenario | Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) |
Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt derivative liabilities | $ 5,562,000 | $ 2,387,000 | |
Oberland Facility | Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Number of potential settlement scenarios | settlementScenario | 4 | ||
Make-whole payment required under each scenario, internal rate of return | 11.50% | ||
Tranche One | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Held to maturity make-whole payment | $ 68,000 | ||
Held to maturity make-whole payment, alternative interpretation | 13,000,000 | ||
Tranche One | Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt derivative liabilities | $ 1,076,000 | ||
Tranche Two | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Held to maturity make-whole payment | 0 | ||
Held to maturity make-whole payment, alternative interpretation | $ 5,000,000 | ||
Tranche Two | Debt derivative liabilities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Debt derivative liabilities | $ 1,961,000 |
Commitments and Contingencies_9
Commitments and Contingencies - Legal Proceedings Narrative (Details) | Feb. 04, 2019 |
Commitments and Contingencies Disclosure [Abstract] | |
Threshold period for not filing response to complaint | 30 days |
Subsequent Events (Details)
Subsequent Events (Details) - Burleson Facility - ft² ft² in Thousands | Jan. 27, 2022 | Oct. 01, 2020 |
Subsequent Event [Line Items] | ||
Area of lease property | 17,500 | |
Subsequent Event | ||
Subsequent Event [Line Items] | ||
Area of lease property | 15,000 |
Schedule II - Valuation and Q_2
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Allowance for doubtful accounts | |||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Balance at Beginning of Year | $ 416 | $ 1,092 | $ 1,117 |
Additions | 0 | 0 | 514 |
Deductions (Charge-offs) | (140) | (676) | (539) |
Balance at End of Year | 276 | 416 | 1,092 |
Valuation allowance for deferred tax assets | |||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Balance at Beginning of Year | 46,517 | 39,932 | 33,876 |
Additions | 6,734 | 6,585 | 6,056 |
Deductions (Charge-offs) | 0 | 0 | 0 |
Balance at End of Year | $ 53,251 | $ 46,517 | $ 39,932 |